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RIASSUNTO 
Presupposti dello studio. Il sequenziamento del DNA è un ambito della biologia 
molecolare in piena evoluzione. Nell’ultimo decennio le tecnologie di 
sequenziamento di nuova generazione – conosciute come Next Generation 
Sequencing (NGS) – sono diventate sempre più diffuse nella pratica clinica. 
Queste nuove tecnologie, per la loro caratteristica di fornire milioni di sequenze di 
DNA per reazione a prezzi contenuti, hanno completamente rivoluzionato 
l’approccio all'analisi del genoma umano. 
 
Scopo della tesi. Lo scopo della tesi è verificare l’applicabilità di metodiche di 
sequenziamento di nuova generazione (NGS) da introdurre nella pratica 
diagnostica di laboratorio. A tal proposito sono state comparate due diverse 
strategie di sequenziamento massivo-parallelo basate sulle due diverse tecnologie 
Illumina e Agilent, che sono state adottate per lo studio dei pazienti in analisi 
presso la U. O. di Genetica ed Epidemiologia Clinica dell’Azienda Ospedaliera di 
Padova.  
L'attività di ricerca si è focalizzata anche sullo sviluppo di modelli per la 
validazione della patogenicità e la caratterizzazione delle varianti geniche 
identificate mediante sequenziamento NGS.  
A tal proposito, il sistema del minigene ibrido è stato utilizzato per verificare la 
capacità di alterare il meccanismo molecolare di splicing di una nuova variante 
nel gene COQ4 identificata in un paziente affetto da sindrome da deficit del 
coenzima Q. E’ stato inoltre sviluppato un sistema di complementazione 
funzionale in lievito S. cerevisiae del gene ASS1 umano, al fine di analizzare e 
validare la patogenicità di alcune mutazioni missenso, identificate in pazienti 
affetti da citrullinemia di tipo 1, con lo scopo di ampliare in futuro l’analisi a 
possibili nuove varianti identificabili. 
 
Risultati e conclusioni. L’analisi comparativa delle metodiche di 
sequenziamento NGS TruSeq Custom Amplicon Low Input Library Prep Kit 
(Illumina) e  HaloPlex HS Target Enrichment System (Agilent Technologies) ha 
dimostrato come quest’ultima sia più performante in ambito diagnostico 
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considerando i paramentri di coverage medio, variabilità dei risultati, capacità di 
discriminare gli pseudogeni, tasso di falsi positivi, numero di ampliconi generabili 
per l’analisi. Per questi motivi dal 2017 stiamo utilizzado solo i pannelli  
HaloPlex HS Target Enrichment System (Agilent).  
L’analisi mediante sequenziamento NGS di 85 pazienti afferenti alla U. O. di 
Genetica ed Epidemiologia Clinica dell’Azienda Ospedaliera di Padova risultati 
positivi allo screening metabolico neonatale per Mucopolisaccaridosi di tipo I 
(MPS I) o per Deficit di Biotinidasi o per Fenilchetonuria (PKU), ha rivelato 
come l’analisi molecolare permetta di distinguere i pazienti veri positivi dai falsi 
positivi allo screening metabolico neonatale, evitando terapie inutili e abbattendo 
notevolmente il costo dell’indagine.  
Il sistema del minigene ibrido utilizzato per la validazione della nuova variante 
IVS4+1G>A nel gene COQ4 si è rivelato essere un metodo efficace e 
relativamente semplice per dimostrare la patogenicità della mutazione in esame: 
essa si comporta come un allele ipomorfo in quanto provoca l'attivazione di un 
sito di splicing criptico a livello dell’esone 4 del gene COQ4 producendo sia il 
trascritto wild-type sia un trascritto più piccolo di circa 100 bp. 
Infine, il modello di lievito S. cerevisiae sviluppato per testare la patogenicità 
delle mutazioni missenso a carico del gene ASS1, ha permesso di classificare i 
mutanti in due classi: mutazioni di classe I che aboliscono completamente la 
crescita del lievito, mutazioni di classe II che consentono una crescita residua. 
Tale sistema è stato utile nel confermare la patogenicità delle mutazioni oggetto di 
studio ma non per stabilire correlazioni tra il genotipo e il fenotipo dei pazienti. 
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ABSTRACT  
Background. DNA sequencing is a field of evolving molecular biology. In the 
last decade, new generation sequencing technologies - known as Next Generation 
Sequencing (NGS) - have become increasingly common in clinical practice. 
These new technologies, by their characteristic, are completely revolutionized to 
the analysis of the human genome. 
 
Aim of the thesis. The aim of the thesis is to verify the applicability of the new 
generation sequencing methods (NGS). In this regard, the Illumina and Agilent 
different massively-parallel sequencing strategies were compared, which were 
adopted for the study of patients analyzed at the Genetics Unit of the Hospital of 
Padua. 
The research activity is also focused on the development of models for the 
pathogenicity validation and the characterization of the genetic variants identified 
by NGS sequencing. 
A new variant in the COQ4 gene was identified in a patient with coenzyme Q 
deficiency syndrome and its potential ability to alter the splicing mechanism was 
studied by hybrid minigene system. 
A functional complementation in S. cerevisiae yeast was performed in order to 
examine and validate the pathogenicity of some missense mutations in the ASS1 
gene, identified in patients with citrullinemia type 1, with the intent to extending 
the analysis to the potential new variants identifiable in the future. 
 
Results and conclusions. The comparative analysis of the NGS technologies 
TruSeq Custom Amplicon Low Input Library Prep Kit (Illumina) and HaloPlex 
HS Target Enrichment System (Agilent Technologies) showed how the second one 
is more efficient in diagnostic, considering the followed parameters: coverage, 
results variability, pseudogenes and false positive discrimination, number of 
amplicons generated for the analysis. For these reason, from 2017 we use only the 
HaloPlex HS Target Enrichment System (Agilent Technologies). 
In the study, 85 patients positive for neonatal metabolic screening for 
Mucopolysaccharidosis type I (MPS I) or for Biotinidase Deficiency or 
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Phenylketonuria (PKU), have been analyzed by Next Generation Sequencing: 
molecular analysis made it possible to distinguish true positive patients from false 
positives to neonatal metabolic screening (it would be important to review the 
cutoff of this screening), allowing to avoid unnecessary therapies and significantly 
reduce the cost of the investigation. 
The hybrid minigene system used for the validation of the new IVS4+1G>A 
variant in COQ4 gene was considered an effective and simple method to 
demonstrate the pathogenicity of the mutation: it behaves like a hypomorph allele 
causing the activation of a cryptic splicing site at exon 4 of the COQ4 gene 
producing both the wild-type transcript and a smaller one less of about 100 bp. 
Finally, the functional complementation in S. cerevisiae yeast system developed 
to test the pathogenicity of missense mutations in the ASS1 gene, allowed to 
classify the mutants in the two classes: class I mutations that completely abolish 
yeast growth, class II mutations that use a residual growth. This system was useful 
to validate the pathogenicity of the mutations studied but not to made correlation 
between the genotype and the phenotype of the patients. 
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1. INTRODUCTION 
 
3.1. DNA sequencing 
DNA sequencing is a field of evolving molecular biology. 
For years most applications have been based on the use of the Sanger method, or 
chain termination method (Sanger et al., 1977), which exploits modified 
nucleotides (didoxynucleotides triphosphates, ddNTPs) to interrupt the DNA 
synthesis reaction in specific positions. This concept allowed the development of 
automated sequencing systems based on this method (Smith et al., 1986) which, to 
date, represents the most accurate sequencing system available and the technique 
of choice in genetic diagnostics. 
In the last decade, however, new generation sequencing technologies known as 
Next Generation Sequencing (NGS) (or, alternatively, Massive Parallel 
Sequencing, MPS, or Second Generation Sequencing, SGS) have become part of 
clinical practice, supplanting the methods used routinely. With the ability to 
provide, at reasonable prices, millions of DNA sequences by reaction, they 
completely revolutionized the way to approach the analysis of the human genome. 
The reduction in costs and times introduced by these tools is a great potential in 
the future of molecular biology. 
 
 
3.1.1.  Sanger sequencing 
Sanger sequencing, also known as first-generation sequencing, was developed in 
1977 by Frederick Sanger (Sanger et al., 1977) and is based on the use of 
modified nucleotides (dideoxynucleotides triphosphates, ddNTPs) to interrupt the 
synthesis reaction of DNA in specific positions. 
From its proposal the method has undergone several evolutions that to date make 
the technique easier and faster, without the use of radioactive substances. 
Currently the Sanger sequencing is based on the clonal amplification of the DNA 
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mold by PCR and on the use of 4 ddNTPs labeled with different fluorochromes 
that allow to conduct the reaction in a single tube (Figure 1). 
 
Figure 1. Method used by Sanger technology based on the use of fluorescent chain 
terminators (taken from Applied Biosystems website, 
https://tools.thermofisher.com/content/sfs/brochures/brochure-ab 
geneticanalyzers.pdf). 
 
The concentration ratio between dNTPs ddNTPs is such that the DNA polymerase 
will statistically terminate the nascent chain in all possible positions, generating 
fragments of different lengths. This approach allowed the implementation of 
automated sequencing methods (Smith et al., 1986; Ansorge et al., 1987) based on 
a capillary electrophoresis system (Swerdlow and Gesteland, 1990) in which a 
polymeric matrix allows the migration of fragments of DNA at different rates 
depending on their length. After the excitation caused by a laser source present at 
the exit from the capillary, the separation of the fragments is followed by 
detecting the fluorescent emissions at different wavelengths of the four 
fluorochromes used as markers. The emissions are collected and analyzed by a 
CCD (Charge-Coupled Device) that processes the different fluorescence signals 
and returns them in the form of a graph called electropherogram, characterized by 
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a succession of peaks of four different colors corresponding to the fluorescent 
emissions of the four different fluorochromes. The raw data obtained from the 
sequencer are assembled and analyzed using dedicated software in order to obtain 
the nucleotide sequence. 
The introduction of capillary electrophoresis for the separation of the marked 
fragments and the implementation of further improvements in Sanger technology 
(Carrilho, 2000, Metzker, 2005) have allowed a considerable increase in the 
processivity, allowing to obtain sequences of length between 600 bp and 1000 bp 
(Hert et al., 2008; Shendure et al., 2008) and sequencing up to 96 samples in 
parallel. The daily output of a current sequencer is around 6 million bases (6 Mb), 
with costs in the order of 500 dollars / Mb (Shendure and Ji, 2008, Kircher and 
Kelso, 2010). 
The most frequently observed sequencing errors are essentially due to the errors 
introduced in the amplification step, to the contamination of the sample under 
examination or to the slippage of the polymerase in correspondence with 
homopolimeric sequences; nevertheless, the average error rate is around rather 
low values, in the order of 10-3. 
 
 
3.1.2.  Next Generation Sequencing (NGS) 
DNA sequencing, based on the traditional Sanger method, the only method 
available until a few years ago, has undergone a sudden acceleration in the last 
decade thanks to the birth of the next generation sequencing technologies (NGS, 
Next Generation Sequencing). The development of platforms that exploit this new 
technology has led to a profound change in the nucleic acid sequencing 
methodology, opening the way to new opportunities in those areas in which DNA 
analysis is the basis of the investigation procedures. 
NGS technologies, which implement a system with greater processivity for 
reading sequences in parallel, are able to produce large amounts of data in a short 
time: think, for example, that NGS HiSeq X Series platforms (Illumina) can 
produce up to 6 billion reads with a sequencing cycle of only 3 days. Parallel to 
this development in terms of throughput, there has been a drastic reduction in 
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terms of costs that led, for example, the sequencing of a Mb to cost less than 1 
dollar against the approximately 10,000 dollars needed to achieve the same result 
in 2000 .  
While NGS technologies have the considerable advantage of being able to 
produce millions of DNA sequences in a single reaction, on the other hand the 
huge amount of data produced still represents an important challenge for 
management and analysis. bioinformatics. Therefore, the implementation of 
systems capable of storing the ever-increasing quantity of data and, in parallel, the 
development of advanced bioinformatics algorithms that make it possible to 
efficiently analyze the data produced, simplifying the biological interpretation, 
have become necessary. 
The NGS technologies allow, compared to the Sanger sequencing, to obtain a 
series of advantages, not only in terms of reduced costs and times, but also in 
relation to the possibility of processing several samples in parallel in a same 
sequencing reaction; the process, known as multiplexing, assigns to the fragments 
of each sample a short nucleotide sequence or barcode that, during data analysis, 
allows their identification and their univocal assignment to the sample to which 
they belong.  
Another typical feature of NGS sequencing is the ability to accurately detect the 
presence of low-frequency alleles, allowing the identification of variations in 
mosaic samples or heterozygous deletions. Unlike the Sanger method, the number 
of times that a fragment of DNA is amplified and sequenced is proportional to the 
abundance of this segment in the original sample so that, through the use of 
specific algorithms in data analysis, it is possible to identify variations in the 
number of copies (CNVs) (Tucker et al., 2009b). 
Given a number of positive aspects and the advantages that derive from it in the 
various areas of molecular biology, however, NGS technology has limitations that 
affect its application. The new generation sequencing platforms available today 
generate sequence reads in shorter meanings (35 - 400 bp) compared to those 
obtained with the traditional Sanger method (500 bp - 1 kb) (Hert et al., 2008). 
This aspect makes the assembly of sequences considerably difficult, especially in 
cases of unknown genomes (sequencing de novo) (Nagarajan and Pop, 2010) or 
with large areas repeated or containing rearrangements. The implementation of 
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paired-end or mate-paired sequencing, which involves the sequencing of DNA 
fragments from the extremities and in opposite directions, has allowed to exceed 
this limit almost completely, allowing the analysis of DNA fragments up to 5 
times long. - 10 kb and being able to identify structural variants in the largest 
human genome of 3 kb (Korbel et al., 2007).  
Moreover, compared to Sanger sequencing, the new generation technologies show 
an error rate in the call of the bases on a higher average: if in the case of capillary 
sequencers on average one reading in a thousand corresponds to an incorrect base 
(10-3), the The error rate of NGS platforms is around values between 0.1% and 
1% (10-3 - 10-2) (Liu et al., 2012). This limit can be largely exceeded by 
increasing the reading depth (coverage or depth, indicating how many times a 
nucleotide is read during the sequencing), ie increasing the number of sequenced 
reads, so as to improve the quality of the experiment and make the product result 
more accurate. From the comparison between first generation and second 
generation sequencing technologies it is easy to understand how NGS techniques 
gave rise to a huge impulse in molecular biology studies thanks to their ability to 
produce a large amount of sequence data in extremely short time reduced, opening 
new fronts of research and allowing the achievement of results until a few years 
ago. The Sanger method, however, due to its high reliability, is still today the 
technique of choice in the clinical-diagnostic practice of nucleic acid sequencing, 
representing the most useful system in the validation of the results obtained by 
NGS technology. 
 
 
3.1.3.  NGS technologies 
In the last decade many platforms have been developed and perfected based on the 
new generation sequencing system, giving rise to a real revolution in the field of 
nucleic acid sequencing, both for the large amount of data produced and for the 
speed with which they are generated. 
Although they differ in the type of biochemistry at the base and in the methods of 
data acquisition and processing, the various NGS platforms share an operational 
workflow divided into four main phases: 
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- preparation of the DNA fragment library; 
- clonal amplification of the fragments; 
- sequencing; 
- bioinformatic analysis of data. 
Below are the different technologies used by second generation NGS platforms. 
 
454 Genome Sequencer FLX (Roche Diagnotics Corporation). The 454 
platform, marketed in 2005 by 454 Life Sciences (now owned by Roche 
Diagnostics Corporation), was the first NGS instrumentation to be launched on 
the market (Margulies et al., 2005). It uses an alternative sequencing technology 
known as pyrosequencing (Ronaghi et al., 1996), based on the determination of 
the presence of the pyrophosphate released after the incorporation of a 
nitrogenous base in the nascent DNA chain. The pyrophosphate acts as a substrate 
for a series of reactions that, through the luciferase enzyme, produce an emission 
of light energy that is detected by a sensor. 
In this system (Figure 2) the double-stranded DNA is fragmented and denatured 
and, at the ends of each fragment, short oligonucleotide sequences, called 
adapters, are required for the subsequent amplification and sequencing steps 
(Figure 2a).  
The fragment library thus constructed is hybridized to 28 μm diameter agarose 
spheres which have complementary adaptive oligonucleotides on their surface. 
The clonal amplification of the fragments takes place by PCR in emulsion 
(emPCR, PCR emulsion) (Dressman et al., 2003): each bead, linked to a single 
type of fragments, is placed in the aqueous phase of an emulsion of water in oil 
containing PCR reagents (Figure 2b). 
After amplification, the spheres are placed in a plate (PTP, picotiter plate) 
consisting of wells of diameter such as to be able to accommodate a single sphere 
(44 μm) (Figure 2c). 
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Figure 2. Method used by technology 454 (Mardis, 2008). 
At this point smaller spheres are added linked to sulfurylase, luciferase, apirase 
and luciferin, enzymes and substrates necessary for the subsequent sequencing 
reaction. Pyrosequencing involves the iterative completion of the nascent DNA 
strand and the simultaneous reading of the signal emitted by the embedded 
nucleotides (SBS, sequencing by synthesis). If the dNTP is complementary to the 
mold strand, its incorporation causes the release of a pyrophosphate which, 
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following the action of sulfurylase, is converted into ATP (Figure 3). The 
produced ATP triggers the reaction of luciferase which, by converting luciferin 
into oxiluciferin, produces light energy in a proportional proportion to the present 
ATP and, consequently, to the number of nucleotides added to the filament. The 
light signal emitted is transmitted through the optical fibers of the plate and 
measured by a CCD (Charge-Coupled Device) which processes it to obtain the 
nucleotide sequence. Non-embedded dNTPs and ATP are degraded by the 
enzyme apirase and the system proceeds with sequencing of subsequent bases. 
 
Figure 3. Schematic illustration of the Pyrosequencing reaction (Ansorge, 2009). 
 
Pyrosequencing has disadvantages especially in the case of homopolymers (ie 
sequences consisting of the same base, for example AAAA): since there is no type 
of DNA chain terminator group, more equal bases can be incorporated at each 
sequencing cycle at the same time and their number can be deduced only from the 
intensity of the light emitted which, in some cases, can be misleading. As a 
consequence, the most frequently observed error using a platform 454 is the 
insertion or deletion of one or more bases, while the single base substitution errors 
are rather rare. Compared to other NGS technologies, this platform produces quite 
long reads, between 200 and 300 bp, which make it particularly suitable for some 
types of applications such as de novo sequencing and metagenomics (Shendure 
and Ji, 2008).  
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The latest version of this tool, known as GS FLX Titanium XL, can produce long 
reads up to 1000 bp with a throughput of 700 Mb per run 
(http://454.com/products/gs-flx-system/index .asp).  
Despite the technological development promoted in recent years, this system has a 
rather high error rate (estimated around an average value of 1%) and not equally 
distributed. The main sources of error are the presence of homopolymers, the 
length of the sequences produced and the spatial location of the spheres in the 
PTP plates (Gilles et al., 2011). 
 
Genome Analyzer (Illumina). Commonly referred to as Solexa by the name of the 
company that introduced it into the market in 2006, this platform is the result of 
Turcatti's work and colleagues on reversible termination sequencing (Fedurco et 
al., 2006; Turcatti et al., 2008) and the merger of four companies - Solexa, Lynx 
Therapeutics, Manteia Predictive Medicine and Illumina. 
The sequencing technology used, and which is currently adopted by most NGS 
platforms, is known as sequencing by synthesis (SBS, sequencing by synthesis); it 
allows, by using dNTPs labeled with four different fluorochromes and using 
reversible chain termination chemistry, the identification of the individual bases 
of a DNA fragment as they are incorporated into the synthesis process of a new 
complementary strand. 
In the initial phase the DNA is fragmented and at the ends of each fragment 
oligonucleotide sequences (adapters) are attached for the subsequent amplification 
process. The fragments of DNA, once denatured, are bound, by one of the two 
ends, to the surface of a slide, called flow-cell, on which are present the 
oligonucleotic sequences complementary to the adapters. The flow-cell, made up 
of eight independent lanes, constitutes the physical support on which all the 
reactions of the instrument take place. The free end of each fragment, hybridizing 
to the complementary oligonucleotide present on the surface of the slide, creates a 
characteristic "bridge" structure that starts the amplification of the fragments. 
Each filament is then cloned through the so-called "bridge PCR" (Adessi et al., 
2000; Fedurco et al., 2006) which generates, for each template, approximately 
1000 identical copies of DNA organized in circumscribed microareas of the flow-
cell called clusters (Figure 4a). 
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Once the clusters have been generated, the amplicons produced come denatured 
and linearised and a sequencing primer acts as a trigger for the actual sequencing 
reaction (Figure 4b). During each cycle, in addition to the DNA polymerase, the 
four suitably modified dNTPs are added to the reaction: each of them is bound to 
a different fluorescent marker and at the end 3'-OH presents a terminator group of 
the reversible chain, so as to to prevent more than one nucleotide being added at a 
time for each sequencing cycle.  
At each cycle a laser excites the fluorescent group bound to the built-in dNTP 
generating a light emission that allows its identification; once the base has been 
assigned, the terminator group present at the 3'-OH and the fluorochrome are 
removed, so as to allow the pairing, and hence the sequencing, of the subsequent 
base. The entire process is repeated until the desired number of cycles is reached 
to be able to sequence the entire length of the fragment of interest.  
The first versions of the platform were characterized by a non-negligible error rate 
and very short reads (around 35 bp), but were able to obtain high throughput at 
low cost. The changes made to the technology and the protocols have significantly 
reduced sequencing errors, even if there are still biases (Nakamura et al., 2011), 
and increased the length of the reads up to 150 bp. In contrast to platform 454, the 
most frequent error is the replacement of a single base (Hutchinson, 2007), while 
insertion or deletion errors are rare. 
Only a few years after the launch of the first platform, Illumina implemented 
paired-end sequencing: each fragment of the library is sequenced from both ends 
and in opposite directions. In this way the technique is more sensitive and 
accurate than the single-end one, in which the fragments are sequenced starting 
from only one of the two ends, since it greatly facilitates subsequent alignment 
operations with the reference sequence. 
The system proposed by Illumina is today the most widespread among NGS 
technologies, both thanks to the high accuracy of the data produced, and to the 
commercial availability of numerous sequencers suitable for different needs. 
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Figure 4. Sequencing technology by synthesis (Mardis, 2008). 
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SOLiD (Applied Biosystems). The SOLiD platform, introduced in the market 
since 2007, originates from the system described by Shendure and colleagues in 
2005 (Shendure et al., 2005) and from the work of McKernan and colleagues 
(McKernan et al., 2006) at Agencourt Personal Genomics (acquired by Applied 
Biosystems in 2006).  
As in system 454, after the denaturing of the double helix and the addition of 
adapters at the ends, the DNA fragments are hybridized into small spheres by 
binding to complementary oligonucleotides that cover the surface. The balls, with 
a diameter of 1 μm, are immersed in an emulsion of water in oil together with the 
reagents for amplification; equally to the 454 system, the fragments are cloned by 
PCR in emulsion (Dressman et al., 2003).  
Once amplification has occurred, the balls are deposited on the surface of a glass 
support which, unlike the PTP plate of 454, does not have any wells: they 
covalently bind to the appropriately treated surface of the plate through the ends 
of the amplified filaments. 
Unlike the previously described technologies that exploit the sequencing by 
synthesis, the SOLiD uses the sequencing by ligation (SBL) (Macevicz, 1998; 
McKernan et al., 2006; Shendure et al., 2005) from which the acronym SOLiD 
stems (Sequencing by Oligonucleotide Ligation and Detection). The sequencing 
reaction is triggered by the hybridization of a primer complementary to the 
adapter linked to the DNA mold (Figure 5) oriented in such a way as to allow the 
ligation to the 5 'end of appropriately constructed probes. Each probe consists of 
an octamer consisting of two specific bases followed by six degenerate bases with 
one of the four fluorescent markers bound to the 5 'end. The two non-degenerate 
bases correspond to one of the 16 possible combinations of base pairs. The last 
three octagon bases can be removed due to a cutting site between bases 5 and 6.  
In the first sequencing cycle, by the action of the DNA ligase, the hybridization of 
the complementary probes to the DNA mold occurs and the consequent emission 
of a fluorescent signal that is detected. The marked portion of the ligated probes 
(last three bases) is cut away so as to regenerate a phosphate group at the 5 'end 
for bonding with the next probe (Figure 5). Seven ligation cycles are repeated in 
sequence to complete the extension of the adapter-bound primer. The newly 
synthesized filament is washed off and a new primer of phase shift sequencing of 
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a base (n-1) is hybridized with respect to the primer used in the previous step (n). 
At each passage new misaligned primers of a base are used with respect to the 
previous ones (n-2, n-3, etc ..., for a total of 5 different primers); this type of 
approach allows each base of the DNA mold to be sequenced twice. 
 
Figure 5. Method used by SOLiD technology (Voelkerding et al., 2009). 
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The nucleotide composition of the DNA template is interpreted on the basis of the 
emission of the fluorophores following the ligation of the various probes. The 
color emitted by each fluorophore allows to identify the couple of the first two 
bases, but it is not sufficient to distinguish one nucleotide from the other. In 
addition to the specific emission of each pair, it is necessary that one of the two 
bases of the sequence is known; this is possible because, thanks to the use of 
phase shift primers, different adapter bases are also sequenced. This information 
provides a starting reference sequence that is used in conjunction with a 2-base 
coding system (in which each pair of adjacent bases is correlated to a specific 
fluorophore) (McKernan et al., 2006) which allows to decipher algorithmically the 
DNA sequence mold (Figure 6).  
In fact, given that each color represents four possible base pairs and for each of 
them the second nucleotide coincides with the first base of the next pair, knowing 
also only a base of the sequence allows to interpret the DNA sequence mold in its 
entirety (Figure 7).  
The length of the reads generated by the SOLiD varies between 25 and 35 bp and 
each stroke of the instrument produces over 4 billion bases (4 Gb). Furthermore, 
thanks to two-base sequencing, accuracy is very high (around 99%). 
Although the performance of the various technologies is constantly evolving and 
the data available are therefore very often conflicting, it is still possible to 
compare the main second-generation platforms available on the market based on 
certain parameters such as accuracy, length of reads and costs . Although each 
instrument presents unique characteristics suitable for certain applications, 
metagenomic experiments conducted with different platforms have shown that, 
within the limit of statistical errors, the results obtained are almost comparable 
(Luo et al., 2012). 
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Figure 6. Sistema di codifica a due basi e ricostruzione statistica della sequenza di 
DNA stampo mediante tecnologia SOLiD. (Voelkerding et al., 2009). 
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Figure 7. Two-base coding system. 
The first base (A) and the order of the detected colors are supposed to be known. 
From the coding scheme it is clear that if the pair is identified by the red color and 
the first base is an A, then surely the second base will be a T. In the second pair, 
the first base is the newly identified T and the color of the pair is green: the 
second base will certainly be a G (Mardis, 2008). 
 
 
3.1.4.  Analysis of NGS data 
The experiments conducted with the new generation sequencing platforms 
generate an unprecedented amount of information (in the order of 1012 bytes, 
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TB), representing an important challenge for the management, archiving and, 
above all, for the bioinformatics analysis of the data (Pop and Salzberg, 2008). 
The NGS data analysis software has different characteristics depending on the 
specific technology of each platform, but on the whole they are based on 
bioinformatic analysis pipelines that convert luminescence or fluorescence images 
acquired by the instrument into nucleotide sequences, called sequence reads. The 
process, which takes the name of base calling, also includes the assignment of a 
quality score for each nucleotide of the read, called Quality Score (QS), which 
indicates the probability of error. The calculation of the Quality Score is based on 
the value of the historical Phred quality score, introduced in 1998 for the analysis 
of the sequence data of the Sanger method (Ewing et al., 1998; Ewing and Green, 
1998). The Phred quality score (q) is calculated as q = - 10 • log10 (e), where e 
represents the probability of incorrect identification of a base. Therefore a 
probability of identifying a base incorrectly equal to 0.1 (10%), 0.01 (1%) or 
0.001 (0.1%) corresponds to a Quality Score of 10, 20 or 30 respectively . 
The data concerning the nucleotide sequence of the reads and the Quality Score 
values associated to each nucleotide are organized into an output file in FASTQ 
format and are used in the subsequent analysis phase consisting in aligning the 
sequence reads produced by the instrument to the sequence of a reference genome. 
The alignment process is rather complex and, in order to be efficient and avoid 
incorrect alignments, requires sequence reads longer than 30 bp. It has been 
shown that while 97% of the E. coli genome can be uniquely aligned with 18 bp 
reads, 30 bp reads uniquely align only with 90% of the human genome (Whiteford 
et al., 2005; Warren et al., 2007). The alignment phase is possible thanks to the 
development and diffusion on the market of numerous software, each based on a 
different alignment algorithm; Examples include BWA (Burrows-Wheeler 
Aligner) software (Li and Durbin, 2009), Bowtie, MAQ (Mapping and Assembly 
with Quality) (Li et al., 2008), SOAP (Short Oligonucleotide Analysis Package) 
and SHRiMP (SHort Read Mapping Package). They also allow the subsequent 
assembly of the reads, in which the read and aligned sequences are combined to 
form the original gene sequence of the input sample. The results obtained from the 
alignment and assembly operations are stored in output files in SAM (Sequence 
Alignment Map) and BAM (Binary Alignment Map) format. 
22 
 
Once the gene sequence of the test sample has been reconstructed, the gene 
positions where the reads differ from it are identified from the comparison with 
the reference genome. The process, known as variant calling, identifies all the 
variants present in the sample under examination, reporting not only 
polymorphisms or mutations, but also any variants deriving from sequencing 
errors. One of the major problems of a variant calling operation is the ability of 
the software to discriminate between variants actually present in the sample under 
examination and variants due to sequencing artifacts or errors in the alignment 
phase.  
The most widely used software for identifying and analyzing variants is the 
GATK (Genome Analysis Toolkit), distributed by the Broad Institute and used in 
two major projects such as the "1000 Genome Project" (http: 
//www.internationalgenome. org /) and the "The Cancer Genome Atlas" 
(https://cancergenome.nih.gov/).  
Other software widely used in the variant calling phase are SOAPsnp, VarScan 
and Atlas 2.  
The variants identified by the variant calling process are stored in a VCF (Variant 
Call Format) file which, in addition to reporting all the identified variants (single 
nucleotide variants (SNVs), insertions / deletions (indels) and other structural 
variants) , contains information related to the chromosomal position, the reading 
depth, the allele frequency, etc, of each of them. 
Since an NGS analysis leads to the identification of a large number of variants 
(especially in the case of whole genome or exome sequencing experiments), it is 
necessary to determine which of these variants, not due to sequencing errors, 
could have a pathogenic meaning, thus reducing the amount of data to be 
analyzed. The filtering process makes use of some rather broad selection criteria, 
but effective in removing variants of little biological significance. Some criteria 
used in filtering operations are:  
- the allelic frequency (the variants with a frequency equal to or higher than 1% 
are probably neutral polymorphisms and therefore can be excluded from the 
analysis);  
- the mode of segregation of variants in the pedigree (all variants compatible with 
a given transmission model are selected);  
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- the comparison between healthy tissue and tumor tissue (if we want to identify 
the somatic mutations developed only in tumor cells, we proceed to the exclusion 
of the variants present in both tissues). 
Once the filtering phase is completed, which has the advantage of considerably 
reducing the amount of data to be analyzed, we move on to the functional 
annotation phase of the variants: the analysis software provides all the data 
available in the databases and/or in literature, indicating whether they are 
polymorphisms, known pathogenetic mutations or entirely new variants and 
therefore of uncertain significance. The annotation phase is rather complex and, 
although it may be automatic, it is often still partially or totally manual; it takes 
into account numerous parameters such as, for example, the results of in silico 
predictions, the possible influence of the surrounding genomic context, any 
modulatory effects on the phenotype even in the absence of a direct pathogenic 
effect and, if existing, the data already published in literature.  
The most commonly used algorithms for the annotation of the variants are SIFT 
(Sorting Intolerant from Tolerant) (Kumar et al., 2009), Polyphen-2 
(Polymorphism Phenotyping v2), ANNOVAR (Wang et al., 2010), SnpEff, 
SNPeffect and VAT (Variant Annotation Tool). 
 
 
3.1.5.  Applications of NGS technologies 
After the first platform was put on the market, NGS technologies have greatly 
accelerated the growth of various sectors of molecular biology, allowing to carry 
out experiments that were previously not technically possible or cost-effective 
from an economic point of view. 
The main applications of NGS technology are described below. 
 
De novo sequencing. De novo sequencing is the determination of the sequence of 
a genome for which no reference data is available.  
The ability of NGS technologies to perform high-throughput analysis has been 
exploited to sequence entire genomes, from those of microorganisms to human 
ones (Sundquist et al., 2007; Chaisson and Pevzner, 2008; Cokus et al., 2008; 
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Durfee et al. ., 2008). As it is understandable, genomics is the area that has most 
benefited from the increase in throughput and the reduction of costs achieved with 
the new generation sequencing techniques. Suffice it to say that today the 
sequencing of the human genome would take a few days against the 10 years that 
were necessary for obtaining the first draft with the Sanger method (International 
Human Genome Sequencing Consortium, 2001).  
 
Sequencing of the transcriptome (RNA-Seq) or microRNAs. RNA sequencing 
provides quantitative information on differences in gene expression levels in 
different tissues or in the same tissue analyzed under different experimental 
conditions (for example, subjected to different treatments) or in different stages of 
development. Compared to microarray of gene expression that allow the analysis 
of only known gene sequences, the RNA-Seq technology is advantageous because 
it allows to characterize the transcripts of a gene without a priori knowledge of the 
sites of the beginning of the transcription (Wang et al., 2009). The technique also 
shows a better ability to distinguish the different RNA isoforms, to determine the 
allelic expression and to detect sequence variations.  
This technique has many applications and has been used to study the 
transcriptomic profile of stem cells (Cloonan et al., 2008), to study alternative 
splicing in human cells (Sultan et al., 2008), as well as for transcriptomic studies 
in numerous organisms, including Saccharomyces cerevisiae and Arabidopsis 
thaliana (Lister et al., 2008; Nagalakshmi et al., 2008). 
 
Resequencing. It is the re-sequencing of an entire genome already sequenced (or 
of a specific portion thereof) that is carried out in order to identify possible 
sequence variations, such as point mutations, insertions, deletions and variations 
in the number of copies (CNVs, Copy Number Variants). This technique has been 
successfully applied to the study of human diseases, allowing the identification of 
new gene loci involved in their etiopathogenesis and the understanding of the 
mechanisms of disease development. 
In addition to the whole genome (whole genome sequencing, WGS), NGS 
platforms can be used to selectively sequence specific genomic regions or specific 
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genes (through targeted resequencing or amplicon sequencing techniques) or to 
obtain information on the whole exome (via whole exome sequencing, WES). 
This latter approach has proved particularly useful for the search for candidate 
genes in polygenic and multifactorial diseases. 
 
Metagenomics. Metagenomics is a branch of genomics that deals with the study 
of microbial communities directly in their natural environment, thus avoiding the 
problem of the cultivation of individual microbial species on selective media.  
NGS technologies have had a huge impact on metagenomics studies, allowing 
access to information that is enormously greater than previously obtained. The 
possible applications are innumerable and include the characterization of human 
microbial communities for clinical purposes and the study of environmental 
microbial populations in order to identify any genes useful for commercial 
purposes such as the production of biofuels or other pharmaceutical or 
agrochemical compounds (Schloss and Handelsman, 2003; Jaenicke et al., 2011). 
 
ChIP Sequencing (ChIP-Seq). The characterization of the regulatory proteins 
associated with DNA has long availed itself of the use of a technique based on 
chromatin immunoprecipitation (ChIP, Chromatin ImmunoPrecipitation) 
followed by hybridization to a microarray (chip) (ChIP-on-chip) (Ren et al., 
2000).  
Thanks to the introduction of the new generation sequencing platforms, ChIP-on-
chip technology has been progressively replaced by ChIP-Seq approaches, in 
which the immunoprecipitated DNA is converted into a fragment library subjected 
to NGS sequencing (Barski et al., 2007; Schones and Zhao, 2008). The 
ChIPSequencing studies conducted to date indicate that this type of technology 
has many advantages compared to the classical ChIP-on-chip approach because it 
allows to obtain a better resolution, as evidenced by the identification of new 
binding sites, and why, like RNA-Seq, it does not require a priori knowledge of the 
genomic regions in which proteins are bound (Johnson et al., 2007, Robertson et 
al., 2007). 
 
 
26 
 
3.2. Mitochondrial diseases 
Mitochondrial diseases are a group of inherited disorders that may derive either 
from alterations in mitochondrial DNA (mtDNA) (Wallace et al., 1999) (Figure 8) 
or from mutations in nuclear genes encoding proteins that participate in oxidative 
phosphorylation.  
 
Figure 8. Map of human mitochondrial DNA.  Diseases due to mutations that 
impair mitochondrial protein synthesis are shown in blue; diseases due to 
mutations in protein-coding genes are shown in red (Di Mauro, 2004). 
These pathologies are very heterogeneous from the clinical point of view; since 
mitochondria are present in all tissues, mitochondrial diseases can affect any 
organ but the most affected are the tissues with the greatest energy demand, 
including muscle, heart, brain and retina. Unlike nuclear DNA (nDNA), mutations 
in mtDNA are inherited through the maternal route and the high variability of the 
clinical phenotype between individuals of the same family or between different 
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families carrying the same mutation is mostly due to phenomenon of 
heteroplasmy, or the coexistence of wildtype and mutated mtDNA molecules. 
Phenotypic changes, at the level of proteins, ribosomes or tRNAs encoded by the 
mitochondrial genome, can potentially alter cellular energy production. Such 
point mutations are believed to lead to a faulty ("leaky") phenotype, in which the 
altered protein or tRNA still function, albeit partially (Scheffler, 1999).  
However, the reduction in efficiency of oxidative phosphorylation (OXPHOS) can 
have significant medical consequences that can occur differentially over time 
(some point mutation diseases are, in fact, at a late onset) or between tissues 
(Scheffler, 1999). Variations in the metabolic structure can in turn induce 
apoptosis of the cells, since the mitochondrial permeability plays a central role in 
the pathway of apoptotic cell death (Liu et al, 1997). 
There are over one hundred mitochondrial genetic diseases, defined, or associated 
or implicated in mtDNA mutations (Kogelnik et al, 1998). The MitoMap website 
contains a list, which is continuously updated and implemented, of mutations of 
the disease-associated / implicated mtDNA (http://www.mitomap.org). 
Human mitochondrial DNA (mtDNA) is a circular double-strand molecule of 
about 16.6 kb. It encodes 2 rRNAs, 22 tRNAs, and 13 polypeptides that are all 
subunits of complexes of the respiratory chain/oxidative phosphorylation system 
that drives oxidative energy metabolism. 
 
 
3.2.1. Coenzyme Q deficiency syndrome 
Mitochondrial diseases are gathered in sindrome. One of them is the coenzyme Q 
deficiency syndrome. 
It was first described in 1989 but only in the last decade the molecular bases of 
this disorder have been elucidated (Doimo et al., 2010). Patients with this 
biochemical phenotype may be classified in two groups, those with primary 
deficiency harbour mutations in one of the genes involved in the biosynthesis of 
CoQ10 while with secondary deficiency is associated to mutations in genes 
unrelated to the CoQ10 biosynthetic pathway or to non-genetic causes (Acosta et 
al., 2016). 
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Coenzyme Q (ubiquinone, Q or CoQ) is a lipophilic molecule ubiquitously 
present in cell membranes, but especially abundant in mitochondria (Turunen et 
al., 2004). It is comprised of a quinone group and of a polyisoprenoid tail of 
variable length in different species: yeast have six units (CoQ6), mice nine 
(CoQ9) and humans ten (CoQ10). 
In mammalian the precursor of the quinone ring is only 4HB, which is derived 
from tyrosine through an uncharacterized set of reactions. The isoprenoid tail is 
synthesized through the mevalonate pathway, which is common also to 
cholesterol biosynthesis (Bentinger et al., 2010). The mevalonate pathway 
comprises the reactions that starting from acetyl-CoA produce farnesyl 
pyrophosphate (FPP). The terminal steps in CoQ biosynthesis are thought to be 
rate limiting for the process in eukaryotes and take place in the mitochondrial 
matrix (Figure 9). 
 
 
Figure 9. The coenzyme Q biosynthetic pathway in mammalian cells (the question 
marks indicate the still uncharacterized enzymatic steps)(Acosta et al., 2016). 
 
Coenzyme Q plays an essential role in energy metabolism due to its redox 
properties. In the respiratory chain it transfers electrons from NADH: coenzyme Q 
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reductase (complex I) and succinate: coenzyme Q reductase (complex II) to 
coenzyme Q: cytochrome c reductase (complex III).  It is also an electron acceptor 
starting from the β-oxidation of fatty acids (Frerman, 1988), from the synthesis of 
uridine (Nagy at al., 1992) and from the oxidation of sulfide to sulfate 
(Hildebrandt et al., 2008). 
The deficit of coenzyme Q is associated with a heterogeneous group of 
predominantly infantile onset diseases. It is difficult to propose a comprehensive 
clinical classification, not only because of the marked clinical differences among 
different genes, but also because of the extremely wide spectrum of clinical 
manifestations among patients with mutations in individual genes. However, it is 
possible to to classify the genetic defects of the CoQ10 biosynthetic pathway 
within three different groups (Acosta et al., 2016):  
- PDSS1, PDSS2, COQ2, COQ6 and ADCK4 genes mutations: these defects 
share common features and are associated with glomerular renal 
involvement manifesting as steroid resistant nephrotic syndrome (SRNS);.  
- COQ4, COQ7 and COQ9 genes mutations: these patients never display 
SRNS, but the main clinical feature is encephalomyopathy. Other 
manifestations include hypertrophic cardiomyopathy, lactic acidosis, and 
(if renal involvement is present) tubulopathy (Emma et al., 2016; Brea-
Calvo et al., 2015; Chung et al., 2015); 
- ADCK3 gene mutations: the main clinical feature is cerebellar ataxia. 
Interestingly these patients have essentially central nervous system 
involvement (other common symptoms are seizures, dystonia, cognitive 
impairment), but have virtually no other extra-CNS manifestations, despite 
a reduction of CoQ10 also in other tissues (Lagier-Tourenne et al., 2008; 
Mollet et al., 2008). 
The treatment of the symptomatology provides for the administration of oral 
supplements of coenzyme Q: 10-30 mg/Kg/day for child and 1000-3000 mg/day 
for adults (Horvath et al, 2012). In most cases the treatment is carried out with the 
oxidized form of coenzyme Q which has a low bioavailability. But more recently 
a treatment with reduced form has been achieved, where the reduced form has 
shown greater bioavailability.  
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Deficit of coenzyme Q associated with diseases such as Parkinson's have been 
described (Shults at al., 2005). In this disease and in other neurodegenerative 
diseases such as Alzheimer's, Huntington's disease or Friedreich's ataxia, 
oxidative damage and mitochondrial dysfunction occur, so the use of coenzyme Q 
as an antioxidant is becoming increasingly relevant (Beal et al.,2004). 
A decrease in the amount of coenzyme Q causes the increasing of the production 
of ROS and oxidative stress that is known is associated with aging (Beyer et al., 
1985; Kalen et al., 1989), so it is believed that a supplementation with Q enzyme 
favors the delay of senescence. 
 
 
3.2.1.1. COQ4 gene 
The COQ4 gene encodes is located on chromosome 9q34.13, and is transcribed 
into a 795 base-pair open reading frame, encoding a 265 amino acid (aa) protein 
(Isoform 1) with a predicted N-terminal mitochondrial targeting sequence. COQ4 
protein has no known enzymatic function, but may be a core component of 
multisubunit complex required for CoQ biosynthesis. 
The human transcript is about 1.4 kb and is expressed ubiquitously, but at high 
levels in liver, lung, and pancreas. Transcription initiates at multiple sites, located 
333–23 nucleotides upstream of the ATG. A second group of transcripts 
originating inside intron 1 of the gene encodes a 241 aa protein, which lacks the 
mitochondrial targeting sequence (isoform 2). Expression of GFP-fusion proteins 
in HeLa cells confirmed that only isoform 1 is targeted to mitochondria (Casarin 
et al., 2008). The functional significance of the second isoform is unknown. 
 
 
3.2.1.2. Splicing regulation 
The pre-mRNA splicing is a critical event for the eukaryotic genes expression: it 
is a complex process that allows the junction of the proteins coding parts (exons), 
which are separated by non-coding sequences (introns). 
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It is considered one of the main mechanisms that allows the generation of 
different proteins from the same gene. 
Knowledge about complexity of the splicing process revealed the existence of 
important elements of regulation (Matlin et al., 2005). Variations of these 
elements, which are found in both coding and non-coding regions of genes, can 
manifest themselves with deleterious effects on the pre-mRNA splicing. 
The correct maturation of the mRNA requires the assembly of a ribonucleoprotein 
complex (the spliceosome) resulting from the coordinated action of 5 small 
snRNPs (small nuclear ribonucleoproteins: U1, U2, U4, U5 and U6) and more 
than 60 polypeptides (Will et al., 2011). 
The splicing regulatory elements are:  
- in cis elements: splicing site at 5' (donor site), site of splicing at 3' 
(acceptor site), branch site, enhancers (ESEs), silencers (ESSs), intronic-
splicing processing element (ISPE)(Figure 10); 
- in trans elements: UsnRNPs (small nuclear ribonucleoproteins), SR 
(serine/arginine rich proteins), HnRNPs (heterogeneous nuclear 
ribonucleoproteins) (Wang and Burge, 2008). 
 
Figure 10. The GU bases of the donor site and AG bases in the acceptor site are 
highly conserved; the base A of the branch site is instead variable. 
The nucleotides belonging to the are highlighted in blue 
more frequent consensus sequences (Cartegni et al., 2002). 
A wrong recognition of the splicing sites between exon and intron or failure 
removal of one or more introns leads to the formation of aberrant mRNA that can 
be unstable and therefore be degraded or can lead to the formation of defective 
protein isoforms or even harmful. 
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Summarizing, the correct separation of the exons from the introns into a 
determined mRNA depends on two factors: 
- the intrinsic strength of splicing sites determined by sequences flanking 
GU and AG; 
- the combination of positive and negative effects due to presence of 
enhancers and silencers. 
It is known that point mutations can cause alterations of the splicing. One of the 
most frequent effects is the skipping of the exon in proximity of the mutation. In 
other cases, the mutation can determine the retention of an intronic fragment or 
activate a "cryptic site" of splicing causing profound modifications of the 
transcript. 
 
 
3.3. Hereditary metabolic diseases and neonatal screening 
Neonatal screening is a public health activity aimed at early detection of some 
congenital diseases. The pathologies subject of neonatal screening, if not 
recognized early, can cause damage often irreversible, especially in the central 
nervous system with consequent severe disability. The identification of these 
diseases in the first days of life is essential to intervene in time and to avoid 
serious consequences on health in the newborn. In fact, the early diagnosis of 
these diseases allows a pharmacological and/or dietetic therapeutic intervention 
aimed at preventing possible harm to the baby's organism.  
Neonatal screening is one of the most important public preventive medicine 
programs. For many of these diseases the treatments carried out after the 
appearance of clinical signs and after episodes of metabolic decompensation are 
not effective and are not able to normalize the clinical picture. 
The neonatal screening program provides that all newborns are submitted free of 
charge to simple tests performed on a few drops of blood taken from the heel of 
the newborn in the first days after birth. Both the basic screening for 3 
pathologies, currently mandatory by law, and the screening extended to more than 
40 diseases can be performed on the same blood sample. The withdrawal is done 
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by the Birth Center, before discharge, and the blood sample is sent to the 
reference Neonatal Screening Centers.  
Diseases subject to neonatal screening are inherited endocrine and metabolic 
diseases which, although singularly rare, reach an incidence of about 1:2000 
births. Hereditary metabolic diseases are genetic diseases that cause the alteration 
of a protein involved in the metabolic processes indispensable for the life of the 
cell such as the production of energy, the elimination of toxic compounds, the 
biosynthesis of compounds essential for its functioning. The onset and severity of 
symptoms depend mainly on the extent of the enzyme defect and on the toxicity 
of the accumulated metabolites. So it must be considered that hereditary metabolic 
diseases are complex diseases and the phenotypic expression for some of them 
can cover a spectrum ranging from mild to more severe forms with a variability of 
onset, if not treated, which can occur in the early months of life or at a more 
advanced age. 
The decision-making criteria for determining whether a disease has the 
characteristics to be included in neonatal screening still refer to those defined in 
1968 by Wilson and Jungner, but the discoveries made in recent decades in the 
field of medical genetics make this topic still open and debated.  
In Italy neonatal screening is currently mandatory throughout the country for 3 
diseases: phenylketonuria, congenital hypothyroidism and cystic fibrosis. The 
introduction of extended neonatal screening (SNE, also known as enlarged 
neonatal screening), marked an epoch-making turning point unthinkable until the 
90s, years in which tandem mass spectrometry was introduced in neonatal 
screening: it was then passed from the basic screening for 3 pathologies to the 
screening for more than 40 pathologies. This profound change has also marked a 
turning point in the clinical history of the pathologies involved, which have finally 
found an instrument of effective treatment in early diagnosis. 
  
 
3.3.1.  Mucopolysaccharidosis type 1 
Mucopolysaccharidosis type 1 (MPS1) is a rare autosomal recessive disease 
caused by mutations in the IDUA gene, coding for alpha-L-iduronidase, which 
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causes gradual accumulation of glycosaminoglycans (GAGs) in all organs and 
tissues (Lorne et al, 2016). This accumulation leads to multisystem clinical 
manifestations of varying severity.  
Historically we recognize three main syndromes that represent the whole 
spectrum of the disease: Hurler (OMIM #607014) (more severe clinical 
phenotype), Hurler-Scheie (OMIM #607015) (intermediate clinical phenotype) 
and Scheie (OMIM #607016) (phenotype less severe clinical). These distinctions 
were made on the basis of the age of appearance of the first symptoms, of the 
rapidity of progression of the pathology and of the pre-eminent symptomatology.  
The incidence is 1/100,000: Hurler's syndrome represents 57%, Hurler-Scheie's 
syndrome 23% and Scheie's syndrome 20%. In severe form (Hurler syndrome or 
MPS I-H), the main symptoms are skeletal deformities and psychomotor 
retardation. It begins at the age of 6-8 months. Other clinical signs are corneal 
opacity, organomegaly, cardiac malformations, short stature, hernias, facial 
dysmorphism and hirsutism. Radiological examination of the skeleton shows 
typical signs of multiple dysostosis. Patients with the intermediate form (Hurler-
Scheie syndrome or MPS I-H/S) have normal or near-normal intelligence, but 
have varying degrees of physical disability (Wraith et al, 1987). The first 
diagnosis is based on the finding of an increase in heparansulphate and dermatan 
sulfate levels in the urine and is confirmed by the measurement of the activity of 
the enzyme alpha-L-iduronidase in the blood.  
Genetic analysis is also available, with a search for mutations in the IDUA gene. 
In pregnancies from couples in which the genetic defect in the parents has already 
been identified, prenatal diagnosis can be performed by villocentesis or 
amniocentesis. The earlier the diagnosis is, the greater the chances that the 
available therapeutic interventions will be effective: for this reason, pilot studies 
for the neonatal screening of this pathology are already under way in Italy 
(Burlina et al, 2018). 
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3.3.2.  Biotinidase deficiency 
Biotinidase deficiency (BTD) (OMIM # 253260) is a congenital defect of biotin 
metabolism that, in the classical form is characterized by convulsions, respiratory 
disorders, hypotonia, skin rash , alopecia, hearing loss and developmental delay 
(Sweetman et al, 1981). It is a rare disease with autosomal recessive transmission, 
due to mutations in the BTD gene which cause a (virtually) complete inactivation 
of the enzyme. The incidence of the clinical deficit of biotinidase is estimated at 
1/61,000 and the frequency of carriers in the general population is about 1/120.  
The treatment of the symptomatology provides for the administration of oral 
supplements of biotin in free form, not related to proteins (Suormala et al, 1990). 
This treatment is given throughout life and no significant side effects are known. 
Some signs, such as optic atrophy, hearing loss or developmental delay, are not 
reversible with biotin treatment. The prognosis of patients with BTD deficiency is 
very good, if they are treated before the onset of symptoms and adhere to the 
intended treatment. 
A more frequent form is characterized by a partial defect. These patients usually 
are compound heterozygotes for a severe BTD mutation and for a relatively 
common p.Asp444His polymorphism (MAF 4% in Europeans). These patients 
display a reduction of BTD (in the range of 20-25% residual activity), are usually 
asymptomatic, but during periods of stress, such as illness, fever or fasting, they 
may develop symptoms similar to those of patients with the classical form. One of 
the main open issues is whether these patients should be treated with biotin or not. 
Individuals homozygous for the p.Asp444His polymorphism do not display 
symptoms and do not require therapy. 
BTD deficiency is identified with neonatal screening when available. The other 
cases are diagnosed based on clinical signs and symptoms and are confirmed by 
demonstrating the defect of BTD activity in serum. The search for mutations in 
the BTD gene is also possible.  
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3.3.3.  Phenylketonuria 
Phenylketonuria (PKU) (OMIM # 261600) is the most common disease of amino 
acid metabolism which, due to lack of treatment, causes mental retardation of 
varying degrees (from mild to severe).  
The incidence of PKU has marked geographical differences and in Europe it is 
estimated to be 1/10,000 live births with a higher rate in some countries such as 
Ireland and Italy. The incidence is particularly high in Turkey where it has been 
calculated in 1/4,000 live births. PKU is much rarer in Finnish, African and 
Japanese populations.  
PKU is an autosomal recessive transmission pathology caused by a wide range of 
mutations in the PAH gene (12q22-q24.2), which codes for phenylalanine 
hydroxylase, an enzyme that catalyzes the hydroxylation of phenylalanine to 
tyrosine, a key enzymatic reaction of the phenylalanine catabolism.  
The many variants of classical PKU are due to the heterogeneity of mutant alleles, 
since many patients are compound heterozygotes rather than homozygous for a 
particular mutant allele (Bartholome at al, 1984). The reduced or absent activity of 
this enzyme results in a neurotoxic effect from hyperphenylalaninemia (Zurfluh et 
al, 2008).  
The normal levels of phenylalanine in the blood are 58 +/- 15 micromoles/liter in 
adults, 60 +/- 13 micromoles/liter in adolescents and 62 +/- 18 micromoles/liter 
(mean +/- SD) in infancy. In the newborn, the upper limit of the norm is 120 
micromoles/liter (2 mg/dl) (Scriver et al., 1985; Gregory et al., 1986). In the 
untreated classical PKU, blood levels of up to 2.4 mM/liter can also be found. 
Pediatric patients also have low plasma tyrosine levels (Hanley et al, 2000).  
The treatment of choice for the forms that require therapy consists in the diet with 
a low content of phenylalanine and mixed amino acids. 
 
 
3.3.4.  Urea cycle disorders 
Urea cycle disorders (UCDs) have an incidence of about 1: 30,000 live births and 
are caused by changes in hepatocyte metabolism induced by a deficiency of one of 
the enzymes involved in the transfer of nitrogen from ammonia to urea, through 
the UC. UDCs are genetic diseases inherited in an autosomal recessive manner, 
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with the exception of the OTC deficit which is an X-linked disease. These defects 
may present an acute picture characterized by rapidly progressive neonatal onset 
that leads to coma and death if a targeted treatment is not promptly started; the 
milder forms can manifest themselves in childhood; asymptomatic patients in 
adulthood have also been described.  
As with most enzyme defects, the pathogenicity of UCDs (Table 1) can be 
attributed to the accumulation of metabolites upstream of the block and / or the 
lack of essential nutrients downstream of the block (Mian and Lee, 2002), but also 
to the lack of different intermediate compounds. 
 
 
Urea cycle disorder Gene 
CPS deficit CPS 
OTC deficit OTC 
Citrullinemia ASS1 
Argininosuccinic aciduria ASL 
Argininemia ARG 
Table 1. UCDs and involved genes. 
However, recent data indicate that the pathogenesis of these diseases is more 
complex. 
Some of the urea cycle enzymes (ASS1 and ASL) are ubiquitously expressed and 
are involved in the production of arginine (Figure 11). Arginine is the precursor of 
important biologically active molecules, including nitroxide (NO), polyamines, 
creatine, proline and glutamate. NO has different physiological functions: it is a 
potent vasodilator, it is involved in neurogenesis and nerve transmission. 
Alterations of the L-arginine-NO pathway may result in the reduction of NO 
levels. In some UCDs, for example in argininosuccinic aciduria, it has been 
shown that the pathogenesis of some chronic complications is related not only to 
hyperammonemia, but also to a tissue-specific deficiency of arginine and 
therefore NO (Nagamani et al., 2012 ). 
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Figure 11. Arginine-citrulline cycle. (Erez et al., 2011). 
 
 
3.3.4.1.  Citrullinemia type 1 
Citrullinemia includes two different conditions: citrullinemia type 1 (CTLN1; 
MIM #215700) and citrullinemia type 2 (CTLN2; MIM #603471).  
CTLN1 is due to deficiency of the enzyme argininosuccinate synthase due to 
mutations in the ASS1 gene, otherwise CTLN2 is caused by Citrin deficiency, a 
mitochondrial carrier aspartate/glutamate Ca2
+
-dependent (Kobayashi et al., 
1999), due to defects in the SLC25A13 gene (7q21.3).  
Citrin forms a complex with ASS1 and the other two cytoplasmic soluble 
enzymes of the urea cycle: mutations in the carrier can cause destabilization and / 
or degradation of this complex, with consequent reduction of the hepatic levels of 
argininosuccinate synthase (Saheki et al. , 2004).  
The classical form of citrullinemia, known as type 1, is an autosomal recessive 
transmission pathology caused by mutations affecting the ASS1 gene and is the 
most common defect among UCDs with an incidence between 1: 44,300 and 1: 
200,000 born live (Woo et all., 2012).  
The clinical picture of this pathology is highly heterogeneous, both as regards the 
age of onset and the severity of the symptoms. It is possible to distinguish two 
main phenotypes: an acute neonatal onset and a later onset subclinical one. 
Arginosuccinate synthase deficiency causes variable degree of hyperammonemia, 
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increased citrulline levels in body fluids (> 1,000 μmol / L, normally <50-60 μmol 
/ L), orotic aciduria, increased and decreased levels plasma glutamine and arginine 
respectively (Woo et al., 2012). The clinical manifestations of the acute form are 
characterized by: loss of appetite, vomiting, tachypnoea, hyperammonaemia, 
lethargy, hypothermia and convulsions with subsequent progression to coma and 
death, if not treated. The late form may instead present with nonspecific 
symptomatology, which includes psychomotor retardation, convulsions, 
sometimes slowing of growth, irritability and behavioral disturbances.  
The introduction in many countries of expanded neonatal metabolic screening 
programs with mass spectrometry has also allowed to identify asymptomatic 
patients with high levels of citrulline (Sander et al., 2003); in these cases the 
molecular analysis identified mutations in both alleles of the ASS1 gene (Haberle 
et al., 2003). The diagnosis of type 1 citrullinemia is based on biochemical criteria 
and is established during the acute phase of the disease by quantifying the plasma 
levels of citrulline (> 1000 μmol / L, normally <60 μmol / L), ammonium and 
glutamine (elevated ), arginine (low), argininosuccinic acid (absent) and increased 
urinary acid excretion in the urine (Haberle et al., 2003). The clinical signs 
described above are indicative of the enzymatic defect of argininosuccinate 
synthase. The biochemical measurement of ASS1 activity can be performed by 
indirect enzymatic assay on cutaneous fibroblasts or hepatic tissue by incubating 
cells with 14C-citrulline and measuring the incorporation of radioactivity into 
proteins via arginine (Kleijer et al., 1984).  
Molecular genetic analysis is performed by sequencing the ASS1 gene, a 
fundamental test also for prenatal diagnosis and for genetic counseling for the 
carrier individuals. Rapid diagnosis and immediate treatment are essential 
elements to prevent neurological damage induced by prolonged 
hyperammonaemia. Therapeutic strategies aim to limit the exogenous and 
endogenous sources of nitrogen-containing compounds and to create alternative 
pathways for its excretion. This result is obtained by following a diet with reduced 
protein intake and with the prevention of catabolic stress that involves the 
mobilization of amino acids from the muscle. An alternative therapy is based on 
the use of scavenger molecules, such as sodium benzoate or sodium 
phenylbutyrate, capable of complexing with glycine and glutamate (nitrogen 
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donors in the urea cycle) favoring their renal excretion (Auron et al., 2012). In 
patients with ASS1 deficiency, the diet is also supplemented with arginine. 
 
 
3.3.4.2.  ASS1 gene 
The human gene ASS1 (MIM #603470) is located on chromosome 9q34.11 where 
it occupies about 63 kb. It includes 16 exons: the start codon is located in the 5' 
region of exon 3 and the termination codon in exon 16.  
Analysis of human genomic DNA demonstrated the presence of 14 copies of the 
argininosuccinate synthase gene, of which 13 are processed pseudogenes, 
distributed in 11 chromosomes including sex chromosomes (Husson et al., 2003).  
The ASS1 promoter extends for 800 bp and contains a TATA box region, 6 
potential Sp1 binding sites (GC boxes) and a potential AP-2 site.  
Three GC regions act synergistically and are required for complete activation of 
the promoter.  
It is known that the expression of ASS1 is regulated by hormones such as 
glucagon, insulin and glucocorticoids but, surprisingly, in the promoter region no 
regulatory elements have been identified as C/EBP or GRE binding sites 
(glucocorticoid responsive elements) .  
The existence of a 10 kb cAMP response element upstream of the transcription 
initiation codon has been demonstrated (Guei et al., 2008) confirming the 
regulatory action of TSE1 (tissue-specific extinguisher locus 1), a hepatic 
enhancer -specific for the expression of ASS1 encoding the regulatory subunit Riα 
of PKA (Boshart et al., 1991). 
 
 
3.3.4.3.  Arginine succinate synthetase enzyme 
The enzyme argininosuccinate synthase (ASS1, EC 6.3.4.5) is a homotetrameric 
protein, each monomer comprises 412 amino acids and has a molecular weight of 
47 KDa. 
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ASS1 is associated with the outer mitochondrial membrane on the cytoplasmic 
side (Karlberg et al., 2007) and expressed ubiquitely, although mainly in the liver. 
In periportal hepatocytes it catalyzes the conversion of citrulline and aspartate into 
argininosuccinate and pyrophosphate by the hydrolysis of ATP, an essential step 
in the process of detoxification of ammonia through the urea cycle (Figure 12). 
ASS1 also performs other functions: as mentioned above, it is involved in the de 
novo synthesis of arginine, in the synthesis of nitric oxide, polyamides and 
creatine (Haines et al., 2011) (Figure 13). 
In the intestinal-renal pathway (Morris et al., 2002), citrulline is produced at the 
level of the small intestine as a product of the metabolism of glutamine and, 
following its release into the bloodstream by the enterocytes, is captured by the 
cells of the renal proximal tubule where it is converted to arginine.  
Different types of non-hepatic cells have the ability to convert citrulline into 
arginine resulting in the generation of nitric oxide by the enzyme nitric oxide 
synthase (NOS).  
It has been shown that the regulation of the expression of ASS1 is tissue-specific: 
in the liver, where the enzyme is expressed at high levels, the main regulation is 
linked to the action of hormones (glucagon, insulin and glucocorticoids) and 
nutrients . More precisely, the expression is induced by glucocorticoids, cAMP 
and glucagon, while insulin and growth hormone act by modulating the effects of 
glucocorticoids.  
In NO-producing cells, instead, ARP (argininosuccinate synthase regulatory 
protein) acts which inhibits the expression of ASS1 at the translation level: only 
10% of the enzyme transcripts contain a uORF encoding this 4.4 kDa inhibitor 
(Haines et al., 2010).  
The expression of argininosuccinate synthase in humans increases progressively, 
from 53% (compared to adults) to the thirteenth week to 90% to the thirty-sixth 
(Husson et al., 2003). Arginine, in fact, is not an essential amino acid in the fetal 
age and in the newborn but it becomes it in adulthood.  
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Figure 12. Reaction catalyzed by argininosuccinate synthase (Haines et al., 2011). 
 
Figure 13. Schematic representation of the three main functions of ASS1 in 
mammals (Husson et al., 2003). 
 
The crystalline structure of the human monomer ASS1, complexed with citrulline 
and aspartate, was determined by Karlberg and colleagues in 2007 (Figure 14). 
The protein is a homotetramer formed from two identical dimers with sequence 
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and structure highly conserved in the different organisms. Each monomer 
comprises two main regions, a globular component that contains a nucleotide 
binding domain (ATP) and an active site with synthase activity, and an α-helix C-
terminal tail involved in oligomerization. The monomers are assembled according 
to the head-tail scheme. 
 
 
Figure 14. Crystallized structure of the human ASS1 protein 
(www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?Dopt=s&uid=106372). 
As can be seen from the topological diagram of a moninero of the 
Argininosuccinate synthase of E. coli (Curis et al., 2005) (Figure 15), the first N-
terminal domain consists of β-sheets alternating with some α -elices and includes 
a P-loop strongly involved in the interaction with ATP. 
The second domain is responsible for the binding of citrulline and the aspartate; 
one of its α-helices is inserted in the middle of the first domain, facilitating the 
dimerization of the monomers at the level of the catalytic site. 
The dimerization takes place mainly at the end of the second domain and 
determines the confinement of the α-helices in a cavity formed by the β-sheets: 
this cavity at the center of the tetramer is occupied by the solvent. 
The structure is stabilized by salt bridges, hydrogen bonds and C-terminal tails 
that embrace the other monomer. 
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Figure 15. Topological diagram of the protein: the triangle represents a β-sheet 
structure while the circle represents an α-helix (tratto da Curis et al., 2005). 
In the active site of each monomer, interaction with a molecule of citrulline and an 
aspartate molecule takes place. 
Citrulline is strongly anchored, by means of salt bridges and hydrogen bonds, to 
the side chains of the residues Glu270, Tyr282, Arg127, Asn123 and Tyr87, the 
two nitrogen atoms bind Ser189 and the oxygen atom interacts with aspartate. 
Aspartate interacts with the residues Asn123 and Thr119 (Figure 16). 
 
Figure 16. Citrulline and aspartate bonds in the ASS1 active site (Karlberg et al., 
2007). 
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In E. coli it has been shown that argininosuccinate synthase undergoes a 
conformational change following ATP binding for the reduction of the distance 
between the phosphate groups of the ATP and the citrulline molecule from 7.9 Å 
to 5.8 Å, the domain of ATP binding approaches the active site, making it 
possible to catalysis (Lemke et al., 2002). 
In humans the distance between citrulline and the phosphate groups of ATP is 
equal to 4.8 Å: this difference indicates that a considerably lower conformational 
change is necessary for the catalysis in ASS1 compared to that demonstrated for 
the bacterial enzyme (Figure 17) . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. ATP-citrulline interaction model in ASS1 (Karlberg et al., 2007). 
 
 
Figure 18. (Figure on the next page) Alignment of the sequence of the 
argininosuccinate synthase protein of different species (H.sapiens, M.musculus, 
S.cerevisiae, T.termophilus, E.coli) using the Multalin software (http: 
//multalin.toulouse. inra.fr/multalin/multalin.html). The arrows indicate the 
conserved residues involved by the mutations under study (in red the highly 
conserved regions are indicated and the partially conserved regions in the different 
species are in blue). 
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3.3.4.4.  Arginine biosynthesis in yeast 
Some of the urea cycle enzymes are involved in arginine biosynthesis and are 
highly conserved (Figure 19). 
The yeast homologues enzymes of the human ornithine-transcarbamylase (OTC), 
argininosuccinate synthase (ASS1) and argininosuccinate lyase (ASL), are ARG3, 
ARG1 and ARG4, respectively. 
The yeast does not need to eliminate the ammonium ions in the form of urea. 
 
Figure 19. Arginine biosynthesis in S. cerevisiae. 
Similarly to humans, also in yeast the first steps of arginine biosynthesis take 
place within the mitochondria and determine the formation of ornithine that is 
exported to the cytoplasm by the transporter Ort1p.  
In the cytoplasm L-ornithine is converted to L-arginine by three reactions 
catalyzed by the enzymes ARG3, ARG1 and ARG4.  
In yeast the transcription of these genes is induced under conditions of amino acid 
deficiency by the transcription factor Gcn4p and is inhibited, in the presence of 
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arginine, by the ArgR/Mcm1p complex comprising Arg80p, Arg81p, Arg82p, and 
Mcm1p (Natarajan et al., 2001).  
The Gcn4p activator interacts with the subunits of the ArgR/Mcm1p repressor 
allowing proper transcriptional regulation in response to the availability of 
arginine (Hinnebusch et al., 1992). Like the human enzyme, Arg1p has tetrameric 
structure: each monomer includes 420 amino acids and has a molecular weight of 
49 kDa.  
The ARG1 gene is located in the XV chromosome, occupies about 1.2 kb and is 
devoid of intronic sequences. 
 
 
3.3.4.5.  Saccharomyces cerevisiae as a model system for 
mutation validation 
S. cerevisiae is a yeast belonging to the phylum of the Ascomycetes. 
It is one of the most used organisms in molecular and cellular biology studies 
thanks to its characteristics: economy, ease of handling, rapidity of growth and 
easy to isolate.  
The S. cerevisiae genome has a length of 1.3x10 bp and contains 16 chromosomes 
ranging in size from 200 to 2200 kb. The total DNA sequence was published in 
1996 and reports 6183 open reading frames (ORF) (Goffeau et al., 1996). 
Although the human genome is 100 times longer, the number of genes is only 3-5 
times greater; this discrepancy is due to the high number of interposed sequences 
and non-coding regions present within the human genome and absent in the yeast 
one. In fact, 30% of yeast genes have a high degree of similarity with human 
genes and 2/3 share at least one conserved domain (Botstein et al., 1997; Walberg, 
2000).  
S. cerevisiae meets cell division by budding from the mother cell and exists in 
both haploid and diploid form. The mating type is determined by the two non-
homologous alleles MATa and MATα, located in the MAT locus of chromosome 
3.  
The two haploid states produce two different pheromones called factor "a" and 
"α": each of the two cell types expresses on its surface the specific receptor for the 
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pheromone produced by the opposite mating type, allowing contact and fusion 
between the two different haploids and the consequent formation of the diploid 
line. The process is reversible, in fact in conditions of nutrient deficiency the 
diploid cell undergoes sporulation by releasing four haploid progenitors, each 
containing two MATa and two MATα cells (Haber et al., 2012). 
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2.  AIM OF THE THESIS 
 
Today's molecular diagnostics makes use of numerous techniques for the 
identification of causative mutations in genes responsible for genetic diseases. 
The most commonly used method and the gold standard f or the identification of 
mutations is the automatic Sanger sequencing, preceded by the amplification of 
the coding sequences of the candidate gene by PCR. However, if the gene is large 
and mutations are distributed along the gene randomly due to the lack of 
mutational hot spots, the Sanger method is rather laborious and requires extremely 
long times, allowing the sequencing of only 96 reactions in parallel. 
The emergence of new generation sequencing methods (NGS) has completely 
revolutionized the fields of molecular biology and genetics; thanks to the high 
processivity, new technologies have given a new impulse to clinical practice, 
facilitating the search for mutations in large genes and reducing costs and analysis 
times. 
The aim of the thesis is to verify the applicability of new generation sequencing 
methods (NGS) to be introduced in the practice of laboratory diagnostics. In this 
regard, two different massively-parallel sequencing strategies were compared 
based on the two different Illumina and Agilent Technologies, which were adopted 
for the study of patients in analysis at the Clinical Genetics Unit of the Hospital of 
Padua. The two approaches used for the analysis of metabolic genetic diseases 
involve the use of genomic DNA as a starting material for the construction of 
libraries and the use of the MiSeq Dx (Illumina) platform for the sequencing of 
samples. 
The research activity has also focused on the development of models for the 
validation and characterization of the gene variants identified by NGS sequencing.  
From the diagnostic point of view, the improvement of the sequencing techniques 
such as the NGS have allowed to identify an ever increasing number of variants 
with the consequent need to study their potential pathogenetic effects. 
For this reason we chose to analyze some variants with uncertain meaning (VUS) 
and potentially able to alter the splicing mechanism using the hybrid minigene 
system. In this study it has been evaluated the possible involvement of the new 
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IVS4+1G>A mutation in the COQ4 gene splicing mechanism, allowing to 
determine its pathogenicity. Since several years the Clinical Genetics Unit invests 
in the study of the molecular mechanisms involved in the coenzyme Q 
biosynthesis pathway and in the characterization of the new mutations identified 
in patients with coenzyme Q deficiency syndrome. 
In this study it was also developed a functional complementation system in S. 
cerevisiae yeast of the human ASS1 gene, in order to analyze and validate the 
pathogenicity of some missense mutations, identified in patients affected by type 
1 citrullinemia. The criteria used to determine the pathogenicity of new sequence 
variants identified in patients affected by monogenic diseases are defined by the 
Mutations Database Initiative/Human Genome Variation Society guidelines, but 
do not provide any functional information on the effects of these mutations; for 
this reason, the development of a system based on S.cerevisiae to evaluate in vivo 
the pathogenicity of the mutated alleles was found to be effective. 
Previous studies (Trevisson et al., 2009; Doimo et al., 2012) have revealed how 
the yeast complementation allows the evaluation of residual activity of the mutant 
forms of the enzyme argininosuccinate lyase, also belonging to the urea cycle: for 
this reason we have decided to apply the same method also for the identification 
of residual activity of the ASS1 mutants, in order to establish possible genotype-
phenotype correlations. 
The ARG1 yeast gene (used as a positive control), the human homologous ASS1 
wild-type gene and the versions containing the mutations under study (inserted by 
site-specific mutagenesis) were cloned into the pCR8 TOPO TA vector and then 
transferred, via recombination LR, in the yeast expression vector pYES.2. With 
these constructs the yeast strain containing a deletion of the ARG1 gene was 
transformed, allowing to obtain a model with which to analyze its residual growth 
capacity in selective medium. Western blot analysis allowed to verify the stability 
of mutant proteins expressed in yeast. 
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3. MATERIALS AND METHODS 
 
3.1. Part I: NGS sequencing analysis 
 
3.1.1. Patients 
The family history and subsequent diagnosis of the patients under examination 
were performed at the U. O. of Genetics and Clinical Epidemiology of the 
Hospital of Padua, according to the diagnostic protocols used in the Operative 
Unit. 
Each patient was asked to provide informed consent for the execution of the 
diagnostic investigation. 
 
 
3.1.2.  Genomic DNA extraction 
Genomic DNA was extracted from leukocyte cells of peripheral blood collected in 
tubes containing EDTA using the MagPurix Blood DNA Extraction kit 200 
(Resnova) commercial kit on MagPurix automatic extractor (Resnova). The 
extraction took place from 400 μl of whole blood and the extracted DNA was 
eluted in 100 μl of Tris-HCl buffer and stored at -20 ° C. 
The quality of the extracted DNA was evaluated by 1.5% agarose gel 
electrophoresis and NanoDrop 2000 spectrophotometer (Thermo Scientific). 
The amount of DNA extracted was measured using the QuantiFluor ONE dsDNA 
System (Promega) kit on the Quantus Fluorometer (Promega) fluorometer. 
 
 
3.1.3.  Mitochondrial genome amplification 
The mitochondrial genome has a double-stranded circular structure and in humans 
it includes 16569 base pairs encoding 37 genes (encoding 13 polypeptides 
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synthesized from the mitochondrial ribosome, 22 tRNA and 2 rRNA), involved in 
the production of proteins necessary for cellular respiration. 
To proceed with NGS sequencing, the entire mitochondrial genome was amplified 
by two overlapping PCRs of approximately 9 kb each using specific pairs of 
primers for each amplified. Primers have been found in the literature 
(Gunnarsdottir et al, 2015). 
Table 2 shows the sequences of primer pairs (forward and reverse) with the 
respective annealing temperatures and the amplified dimensions. 
Amplicon Primer FOR (5’->3’) Primer REV (5’->3’) Bp Ta 
1 gacgggctcacatcaccccataa gcgtacggccagggctattggt 8338 68.5 °C 
2 gccacaactaacctcctcggactcct ggtggctggcacgaaattgacc 8647 66 °C 
 
Table 2. Primers used for the amplification of the human mitochondrial genome, 
with the respective amplified dimensions and annealing temperatures. 
The PCR amplification was performed in a volume of 25 μl according to the 
protocol shown in Table 3, using the Expand Long Template Taq (Roche) enzyme 
and subjecting the reaction to the temperature cycle described in Table 4. The 
presence of products PCR was verified by 1.5% agarose gel electrophoresis. 
Reaction mix Volume 
H2O milliQ  29.25 µl 
Buffer 1 10X 5 µl 
dNTPs 10 mM 7 µl 
Primer forward 10 µM 1.5 µl 
Primer reverse 10 µM 1.5 µl 
Long Template Taq 0.75 µl 
DNA 5 µl 
Total 50 µl 
Table 3. Mix of the amplification reaction (PCR) of human mitochondrial 
genome. 
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Temperature Time N° of cycles 
94 °C 2' 1 
94 °C 10'' 
10 Ta 30'' 
68 °C 8' 
94 °C 15'' 
25 Ta 30'' 
68 °C 8' + 20''/ciclo 
68 °C 7' 1 
 
Table 4. Thermal profile of the amplification reaction (PCR) of human 
mitochondrial genome. 
 
 
3.1.4.  Construction of NGS libraries according to the Nextera 
XT DNA Library Prep Kit (Illumina) 
NGS sequencing of mitochondrial DNA was performed according to the Nextera 
XT DNA Library Prep Kit (Illumina) commercial kit protocol. The protocol uses 
PCR amplicons (> 300 bp) as starting material and provides for the fragmentation 
of DNA and the simultaneous "tagging" of the fragments obtained with 
oligonucleotide sequences (adapters) necessary for the primers to appear in the 
next step. This is followed by PCR amplification of the obtained fragment library 
which inserts, at the ends of the fragments, both the adapters for the generation of 
clusters on the flow-cell and the index sequences for the identification of each 
sample. 
Below is a description of the subsequent steps provided for the construction of the 
bookcases. 
 
Quantification and dilution of mitochondrial DNA amplicons. The 
mitochondrial DNA amplicons of each patient were quantified using the 
QuantiFluor ONE dsDNA System (Promega) kit on the Quantus Fluorometer 
(Promega) fluorometer and, taking into account the size of each amplified, their 
molarity was calculated. Each amplicon was diluted to 5 nM and, after combining 
all the amplicons of each patient in a single tube, a pool dilution of 0.2 ng/μl was 
prepared. 
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Tagmentation. 5 μl of each amplicon pool at 0.2 ng/μl (1 ng) were incubated with 
10 μl of Tagment DNA Buffer and 5 μl of Amplicon Tagment Mix at 55 °C for 5 
minutes and cooled to 10 °C. The transposome was immediately inactivated by 
adding 5 μl of Neutralize Tagment Buffer to the reaction and incubating at room 
temperature for 5 minutes. 
 
Library amplification. At the reaction of the previous step, 15 μl of Nextera PCR 
Master Mix, 5 μl of primer index 1 and 5 μl of primer index 2 were added. The 
samples were subjected to a PCR program defined as follows: 
- 72 ° C for 3 minutes 
- 95 ° C for 30 seconds 
- 12 cycles of: 
- 95 ° C for 10 seconds 
- 55 ° C for 30 seconds 
- 72 ° C for 30 seconds 
- 72 ° C for 5 minutes 
- 10 ° C ∞ 
 
Purification of amplified libraries. 30 μl of magnetic beads (AMPure XP beads, 
Beckman Coulter) were added to the 50 μl of PCR of the previous step and 
incubated at room temperature for 5 minutes. The plate was transferred onto a 
magnetic support and, after the migration of the marbles, the supernatant was 
removed and eliminated. The beads were washed in two successive steps adding 
200 μl of 80% fresh prepared ethanol. Once the ethanol was removed, the 
magnetic beads were allowed to dry at room temperature for 15 minutes. Then the 
beads were resuspended by adding 52.5 μl of Resuspension Buffer and incubated 
at room temperature for 2 minutes. The plate was again transferred onto a 
magnetic support and, after the migration of the beads, 50 μl of supernatant were 
removed and transferred to a new plate. 
 
Library control. The quality of the libraries obtained was evaluated by subjecting 
1 μl of each capillary electrophoresis library to 2200 TapeStation  (Agilent 
Technologies)  using the chips and reagents of the High Sensitivity D1000 Reagents 
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(Agilent Technologies). Good quality libraries show fragments between 250 bp 
and 1000 bp. 
 
Manual normalization of libraries. The normalization of the libraries was 
performed manually rather than through passages with magnetic beads as required 
by the protocol. The libraries were quantified using the QuantiFluor ONE dsDNA 
System (Promega) kit on the Quantus Fluorometer (Promega) fluorometer and, 
taking into account the average fragment size of each library calculated from the 
Bioanalyzer, were diluted to 3 nM in a final volume of 10 μl. 
 
Preparation of libraries for loading on MiSeq Dx. 5 μl of each 3 nM library were 
collected and merged into an equimolar pool. 10 μl of the library pool were 
denatured with 10 μl of 0.2 N NaOH at room temperature for 5 minutes. The pool 
(1.5 nM) was further diluted in Hybridization Buffer (HT1) in two steps up to the 
final molarity of 10 pM. 
The libraries were uploaded to MiSeq Dx (Illumina) along with a library of control 
(PhiX Control v3, Illumina) at 1%. 
 
 
3.1.5.  PCR-RFLP analysis for the confirmation of 
mitochondrial mutations 
The confirmation of mitochondrial mutations identified with the Nextera XT DNA 
Library Prep Kit (Illumina) was performed by PCR-RFLP analysis (PCR 
amplification followed by enzymatic digestion) that allows to identify the 
presence of the mutation even at low percentages of heteroplasmy. 
The target regions of the mitochondrial genome were amplified by PCR, each 
using pairs of specific primers for each amplified. The primers were designed 
using the Primer3 software (http://primer3.ut.ee/) available online. 
Table 5 shows the sequences of primers pairs (forward and reverse) with the 
respective amplified size of the main mutations identified by the mitochondrial 
genome (of which m.15170G>A has been identified for the first time). For all 
reactions the annealing temperatures was 55°C. 
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Mutation 
Primer FOR 
(5’->3’) 
Primer REV  
(5’->3’) 
Bp 
m.3243A>G CCAGGTCGGTTTCTATCTAC AGAGTTTTATGGCGTCAGCG 386 
m.3460G>A TCCTAATGCTTACCGAACGA TCTTTGGTGAAGAGTTTTATCG 121 
m.11778G>A CCATCTGCCTACGACAAACA TCCTTGAGAGAGGATTATGACG 223 
m.14484T>C ACTCACCAAGACCTCAACC GATTGTTAGCGGTGTGGTCG 176 
m.15170G>A TGAAACTTCGGCTCACTCCT TTTTATCGGAATGGGAGGTG 562 
 
Table 5. Primers used for the amplification of the target regions for the main 
mutations of the human mitochondrial genome, with the respective amplified 
dimensions and annealing temperatures. 
The PCR amplification was performed in a volume of 25 μl according to the 
protocol reported in Table 6, using the enzyme Taq Gold (Applied Biosystem) and 
subjecting the reaction to the temperature cycle described in Table 7. The 
presence of products of PCR was verified by 1.5% agarose gel electrophoresis. 
Reaction mix Volume 
H2O milliQ 14.85 µl 
Buffer 10X 2.5 µl 
MgCl2 1.5 µl 
dNTPs 10 mM 0.5 µl 
Primer forward 10 µM 1.75 µl 
Primer reverse 10 µM 1.75 µl 
Taq Gold 0.15 µl 
DNA 2 µl 
Total 20 µl 
 
Table 6. Amplification reaction (PCR) mix of target regions for main mutations of 
the human mitochondrial genome. 
Temperature Time N° of cycles 
95 °C 10' 1 
95 °C 30'' 
35 Ta 40'' 
72 °C 1' 
72 °C 10' 1 
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Table 7. Thermal profile of the amplification reaction (PCR) of the target regions 
for the main mutations of the human mitochondrial genome. 
After amplification, an enzymatic digestion was performed using the restriction 
enzymes reported in Table 8. 
Mutation 
Restriction 
enzyme 
T of incubation BSA 
Inactivation at 
65 °C for 20' 
m.3243A>G ApaI 25 °C Yes Yes 
m.3460G>A BstUI 60 °C No No 
m.11778G>A BstUI 60 °C No No 
m.14484T>C BccI 37 °C No Yes 
m.15170G>A AcuI 37 °C No Yes 
Table 8. Restriction enzymes used for enzymatic digestion of the target regions 
for the main mutations of the human mitochondrial genome. 
The enzymatic digestion reaction (RFLP) was performed in a volume of 20 μl 
(Table 9) using the specific restriction enzyme and incubating the reaction to the 
respective incubation T (Table 8) overnight. The presence of RFLP products was 
verified by 12% acrylamide gel electrophoresis. 
Reaction mix Volume 
H2O milliQ To 20 µl 
Buffer CutSmart 10X 2 µl 
BSA 10X 2 µl 
Restriction enzyme 1 µl 
PCR product 500 ng 
Table 9. Enzymatic digestion reaction mix. 
 
 
3.1.6.  Construction of NGS libraries according to the TruSeq 
Custom Amplicon Low Input Library Prep Kit (Illumina) 
The analysis of hereditary metabolic diseases based on NGS sequencing is 
performed using the two different TruSeq Custom Amplicon Low Input Library 
Prep Kit (Illumina) and HaloPlex HS Target Enrichment System (Agilent 
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Technologies) technologies. These are two amplicon-based methods based on the 
generation of DNA amplicons from small amounts of the patient's genomic DNA, 
using customized oligonucleotides as primers for amplification, for capture and 
enrichment of regions of interest. 
TruSeq Custom Amplicon Low Input Library Prep Kit (Illumina), after the 
hybridization of the DNA of each patient to the custom probe pool, provides a 
step of extension and ligation of the portion of DNA between the two probes that 
leads to the formation of products containing the target regions of interest flanked 
by short sequences complementary to the primers of the subsequent amplification 
step. PCR, in addition to cloning regions of interest, adds adapters for the 
generation of clusters on the flow-cell and the specific index sequences for each 
sample. 
Below is a description of the subsequent steps envisaged for the construction of 
the bookcases. 
 
Design the probe pool. The probes of our gene panels were previously designed 
using the DesignStudio software (Illumina). 
Each panel generates an average of 600 amplicons long on average 250 bp and 
has an average coverage of 99.71%. 
 
Quantification and dilution of genomic DNA. DNA samples were quantified 
using the QuantiFluor ONE dsDNA System (Promega) kit on the Quantus 
Fluorometer (Promega) fluorometer and diluted to the final concentration of 25 
ng/μl in 10 mM Tris-HCl in a final volume of 25 μl. 1 μl of each DNA was 
aliquoted in plate and diluted by adding 3 μl of Resuspension Solution 1 and 1 μl 
of Sample Stabilization Solution 1. A positive control, provided by the kit, and a 
negative control were also added to the plate. 2 μl of 2800M control DNA was 
diluted with 2 μl of Resuspension Solution 1 and 1 μl of Sample Stabilization 
Solution 1 while the negative control consists in 5 μl of Resuspension Solution 1. 
 
Hybridization of the probe pool. To each sample were added 5 μl of the custom 
probe pool (Custom Amplicon Oligo Tube) previously diluted with Resuspension 
Solution 1. To the positive control were added 5 μl of a specific probe pool 
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(Control Oligo Pool kit) previously diluted with Resuspension Solution 1. 15 μl of 
Oligo Hybridization for Sequencing 2 were added to all samples. The samples 
were incubated in thermomixer at 95 °C for 1 minute and the temperature was 
subsequently lowered to 40 ° C. 
 
Removal of unbound probes. 25 μl of Sample Purification Beads were added to 
the reaction of the previous step and incubated at room temperature for 5 minutes. 
After transferring the plate onto a magnetic support, the supernatant was removed 
and discarded. The beads were washed three times with 80 μl of Stringent Wash 1 
and then with 80 μl of 60% prepared fresh ethanol. The supernatant was removed 
and the ethanol was evaporated at room temperature for 5 minutes. 
 
Extension and ligation of the bound probes. To each sample were added 22 μl of 
a mixture of Extension-Ligation Enzyme and Extension-Ligation Buffer previously 
prepared. The samples were subjected to the following thermal extension and 
ligation program: 
- 37 ° C for 45 minutes 
- 70 ° C for 20 minutes 
- 4 ° C ∞ 
 
Library amplification. At the reaction of the previous step were added 4 μl of 
Index 1 (i7), 4 μl of Index 2 (i5) and 20 μl of a mix of Enhanced Master Mix and 
Enhanced DNA Polymerase. 
The samples were subjected to a PCR program defined as follows: 
- 95 ° C for 3 minutes 
- 28 cycles of: 
- 98 ° C for 20 seconds 
- 67 ° C for 20 seconds 
- 72 ° C for 40 seconds 
- 72 ° C for 1 minute 
- 10 ° C ∞ 
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Purification of amplified libraries. After centrifuging, 45 μl of supernatant was 
taken from each sample and transferred to a new plate. 36 μl of Sample 
Purification Beads were added and the plate was incubated first at 1800 rpm for 2 
minutes and then at room temperature for 5 minutes. The plate was transferred 
onto a magnetic support and, after the migration of the beads, the supernatant was 
removed and discarded. The beads were washed in two successive steps adding 
200 μl of 80% fresh prepared ethanol. Once the ethanol was removed, the beads 
were allowed to dry at room temperature for 5 minutes. To resuspend the beads, 
25 μl of Resuspension Buffer were added and the plate was incubated first at 1800 
rpm for 2 minutes and then at room temperature for 2 minutes. After relocating 
the plate on a magnetic support to allow the migration of the beads, 20 μl of 
supernatant were removed and transferred to a new plate. 
 
Library control. The quality of the libraries obtained was evaluated by an 
electrophoretic run on 4% agarose gel. The PCR products of the samples have a 
size of about 350 bp, as expected for amplicons of 250 bp. 
 
Manual normalization of libraries. The normalization of the libraries was done 
manually. The libraries were quantified using the QuantiFluor ONE dsDNA 
System (Promega) kit and the Quantus Fluorometer (Promega) fluorometer. 
Then the molarity was calculated using the expected length of PCR products (350 
bp). Finally, the libraries were diluted to 3 nM in a final volume of 100 μl. 
 
Preparation of libraries for loading on MiSeq Dx. 5 μl of each 3 nM library were 
collected and mixed into an equimolar pool. 10 μl of the library pool were 
denatured with 10 μl of 0.2 N NaOH at room temperature for 5 minutes. The pool 
(1.5 nM) was further diluted in Hybridization Buffer (HT1) in two steps up to the 
final molarity of 10 pM. 600 μl of the pool was loaded on MiSeq Dx (Illumina) 
with a control library (PhiX Control v3, Illumina) at 1%. 
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3.1.7.  Construction of NGS libraries according to the  HaloPlex 
HS Target Enrichment System (Agilent Technologies) 
The other amplicon-based NGS technology that has been used for the analysis of 
inherited metabolic diseases is HaloPlex HS Target Enrichment System (Agilent 
Technologies). 
An enzymatic digestion step of the genomic DNA of each patient precedes the 
hybridization to the custom probe pool.  
Below is a description of the subsequent steps envisaged for the construction of 
the bookcases. 
 
Design of the probe pool. The probes of our gene panels were previously 
designed using the SureDesign software (Agilent Technologies). 
Two types of panels have been designed: medium-sized panels that generate an 
average of 4500 amplicons, and large panels that produce an average of 16,000 
amplicons. In both cases the amplicons are 150 bp long and the panels have an 
average coverage of 99.8%. 
 
Quantification and dilution of genomic DNA. DNA samples were quantified 
using the QuantiFluor ONE dsDNA System (Promega) kit and the Quantus 
Fluorometer (Promega) fluorometer. DNA were diluted to the final concentration 
of 1.8 ng/μl in 10 mM Tris-HCl in a final volume of 32 μl. The 32 μl of each 
genomic DNA were transferred to the respective well of an 8-well strip (DNA 
Sample Strip), in which there was also transferred 32 μl of ECD (Enrichment 
Control DNA) provided by the kit. 
 
Preparation of Restriction Enzyme Master Mix. 16 different restriction enzymes 
are provided in two 8-well strips (Green Enzyme Strip and Red Enzyme Strip), 
named from A to H. Using a multichannel pipette 0.35 μl of each enzyme of the 
Green Enzyme Strip and Red Enzyme Strip have been aliquoted in the respective 
wells of the Restriction Enzyme Master Mix Strip, to which were then added 24.6 
μl of RE buffer and 0.64 μl of BSA solution. 
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Digestion of genomic DNA with restriction enzymes. Using a 3.5 μl multichannel 
pipette, enzymes were aliquoted from the Restriction Enzyme Master Mix into 
each column of a 96-well plate (Restriction Digest Reaction Plate). Each column 
contains 3.5 μl per well of the same combination of restriction enzymes. 
3.5 μl of each genomic DNA previously aliquoted in the DNA Sample Strip, were 
distributed in the respective column of the Restriction Digest Reaction Plate. In 
the last column of the plate, 3.5 μl of the ECD were aliquoted. 
The plate was briefly centrifuged and then transferred to the thermocycler for the 
digestion reaction: 
- 37 ° C for 30 minutes 
- 80 ° C for 5 minutes 
- 4 ° C ∞ 
 
Digestion validation. Enzymatic digestions were validated by electrophoretic 
analysis of ECD reactions with the TapeStation 2200 (Agilent Technologies) 
instrument and using High Sensitivity D1000 ScreenTape (Agilent Technologies) 
and High Sensitivity D1000 Reagents (Agilent Technologies). 
ECD includes genomic DNA and a 800 bp PCR product that contain restriction 
sites for all enzymes used in digestion reactions. The results of the electrophoretic 
run were visualized with the 2200 TapeStation Analysis (Agilent Technologies) 
software: the 8 digestions must show three predominant bands at about 125, 225 
and 450 bp. 
 
Hybridization of digested DNA to HaloPlex HS probes. The 8 digestion reactions 
of each patient were transferred to the respective tube for hybridization with the 
custom probes. To each tube were added 5 μl of the specific HaloPlex HS Probe, 
34 μl of Hybridization Solution and 5 μl of HaloPlex HS Indexing Primer (unique 
for each patient). 
The tubes were briefly centrifuged and then transferred to the thermocycler for the 
hybridization reaction: 
- 95 ° C for 5 minutes 
- 58 ° C for 2 hours 
 
65 
 
Elimination of the hybridization buffer. For each sample to be purified a mix was 
prepared by combining 20 μl of HS Hybridization Stop Solution and 80 μl of 
AMPure XP (Beckman Coulter) beads. 100 μl of the mix were added to each 
sample which was then incubated at room temperature at 1300 rpm for 5 minutes. 
The tubes were transferred onto a magnetic support and, after the migration of the 
beads, the supernatant was removed and eliminated. The beads were washed in 
two successive steps adding 200 μl of fresh prepared 70% ethanol. Once the 
ethanol was removed, the beads were allowed to dry at room temperature for 5 
minutes. 
 
Ligation of the captured fragments. The beads were resuspended by adding 50 μl 
of the ligation mix obtained by combining, for each sample, 10 μl of HS Ligation 
Solution, 0.6 μl of 1 mM rATP and 39.4 μl of H2O nuclease free. 
The tubes were incubated at room temperature for 2 minutes to allow the DNA to 
elute from the beads and then transferred back to a magnetic support. 47.5 μl of 
supernatant were taken and transferred to new tubes which, after adding 2.5 μl of 
the enzyme HS DNA Ligase, were incubated at 55 ° C for 10 minutes in the 
thermocycler. 
 
Capture the target DNA. 40 μl of Dynabeads MyOne Streptavidin T1 magnetic 
beads (Thermo Fisher Scientific) diluted in HS Capture Solution were added to 
each sample. The samples were then incubated at room temperature for 15 
minutes. The tubes were transferred onto a magnetic support and, after the 
migration of the beads, the supernatant was removed and eliminated. 
Subsequently 100 μl of Wash 1 mix was added, combining 90 μl of HS Wash 1 
Solution and 10 μl of fresh 1 M NaOH. The tubes were incubated at room 
temperature for 1 minute and then transferred back to a magnetic support to 
remove the Wash 1 mix. After adding 150 μl of HS Wash Solution 2 to each 
sample, the tubes were transferred to the magnetic media and the supernatant was 
removed. 
 
Library amplification. The target libraries captured in the previous step were 
amplified by PCR adding 100 μl of PCR master mix to the washed beads as 
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follows: 53.2 μl of nuclease-free H2O, 30 μl of Herculase II Reaction Buffer, 0.8 
of 100 mM dNTPs, 4 μl of Primer 1, 8 μl of Primer 2, 4 μl of Herculase II Fusion 
DNA Polymerase. 
The samples were submitted to the following PCR program: 
- 98 ° C for 2 minutes 
- N cycles (the number is variable for each panel) of: 
- 98 ° C for 30 seconds 
- 60 ° C for 30 seconds 
- 72 ° C for 1 minute 
- 72 ° C for 10 minutes 
- 8 ° C ∞ 
When the PCR program was completed the tubes were briefly centrifuged and 
transferred onto a magnetic support. 40 μl of supernatant were taken and 
transferred to new purification tubes. 
 
Purification of amplified libraries. To the 40 μl of each sample, 100 μl of 
AMPure XP beads (Beckman Coulter) and 40 μl of nuclease-free H2O were 
added. The tubes were incubated at room temperature for 5 minutes and then 
transferred onto a magnetic support to remove the supernatant. The beads were 
washed in two successive steps adding 200 μl of fresh 70% ethanol. Once the 
ethanol was removed, the beads were allowed to dry at room temperature for 5 
minutes. To resuspend the beads 45 μl of HS Elution Buffer were added. The 
beads were incubated at room temperature for 2 minutes. After relocating the plate 
on a magnetic support to allow the migration of the beads, 40 μl of supernatant 
were removed and transferred into new tubes. 
 
Library validation. The quality of the libraries obtained was measured by 
electrophoretic analysis with the TapeStation 2200 (Agilent Technologies) 
instrument and using High Sensitivity D1000 ScreenTape (Agilent Technologies) 
and High Sensitivity D1000 Reagents (Agilent Technologies). 
The PCR products of the samples are between 175 and 625 bp. 
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Preparation of libraries for loading on MiSeq Dx. 5 μl of each 4 nM library were 
collected and mixed into an equimolar pool. 10 μl of the library pool were 
denatured with 10 μl of 0.2 N NaOH at room temperature for 5 minutes. The pool 
(2 nM) was further diluted in Hybridization Buffer (HT1) in two steps up to the 
final molarity of 10 pM. 600 μl of the final pool were loaded on MiSeq Dx 
(Illumina) with a control library (PhiX Control v3, Illumina) at 1%. 
 
 
3.1.8.  NGS sequencing and data analysis 
The libraries of each sample were sequenced by paired end method (2x150 bp) on 
MiSeq Dx platform with chemistry v2 (MiSeq Reagent Kit v2, Illumina) with an 
expected coverage not less than 500X. 
The minimum threshold of the Quality Score has been set to 30 (QS30): the 
instrument has performed the "call of the bases" (base calling) with an accuracy of 
99.9% (probability of 1/1000 to call the wrong base) . 
For libraries made according to the Nextera XT DNA Library Prep Kit (Illumina), 
during the sample sheet preparation phase was chosen the "small genome 
resequencing" analysis pipeline. To simplify the analysis, the reads produced by 
the instrument were aligned not to the entire human genome (GRCh37/hg19), but 
to the reference sequence of the human mitochondrial genome 
(human_mtDNA_16569_bp_andersen). 
The "small genome resequencing" pipeline uses BWA software (Burrows-
Wheeler Aligner) (Li and Durbin, 2009) and GATK (Genome Analysis Toolkit) 
for the alignment and for call phases of the variants, respectively. 
For libraries made according to the TruSeq Custom Amplicon Low Input Library 
Prep Kit (Illumina) a "targeted resequencing" approach was adopted: the 
sequencing of the target regions and the subsequent alignment of the reads to the 
sequence reference was made thanks to the information contained in the "manifest 
file", a specific file containing the indications relating to the chromosomal 
position of the amplicons designed, and the choice of the human genome (Homo 
sapiens, hg19) as the reference genome. This pipeline exploits the Smith-
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Waterman algorithm for alignment of the reads and the GATK (Genome Analysis 
Toolkit) software for the call of the variants. 
The secondary analysis of libraries generated by Illumina protocols, the MiSeq 
Reporter v2.5.1.3 (Illumina) and VariantStudio v2.2 (Illumina) software were 
used in combined with IGV v2.1.2 software (Integrative 61 Genomics Viewer - 
Broad Institute) to allows the graphical display of aligned reads and variants. 
For libraries made according to the HaloPlex HS Target Enrichment System 
(Agilent Technologies) protocol, the samplesheet was set up to generate only 
FASTQ files, a text format used to represent sequences. FASTQ files are the main 
inputs for alignment. The analysis was performed using the SureCall software 
(Agilent Technologies) that uses the BWA software (Burrows-Wheeler Aligner) 
(Li and Durbin, 2009) for alignment and the SAMtools software for the call of the 
variants. 
The run parameters of the MiSeqDx instrument, generated by the RTA v1.18.54.0 
(Real Time Analysis) software integrated into the instrument, were evaluated in 
real time using the Sequencing Analysis Viewer software v1.8.37.0 (Illumina). 
Once the variants of interest were identified, a search was carried out in the 
literature and in the various databases available online (LOVD, Leiden Open 
Variation Database, http://www.lovd.nl/3.0/home, and HGMD, Human Gene 
Mutation Database, Institute of Medical Genetics, Cardiff, http://www.hgmd.org/) 
to verify if mutations had a pathogenic clinical significance already described. 
 
 
3.1.9.  MLPA analysis 
Patients analyzed by NGS sequencing which shows only one mutation in 
heterozygosis in the PAH gene, were tested by MLPA analysis (Multiplex 
Ligation-dependent Probe Amplification) to check the presence of 
deletions/duplications of one or more exons of the PAH gene. 
MLPA analysis was conducted according to the protocol of the SALSA MLPA 
P055 commercial kit (MRC-Holland). 
In the first step 3 μl of DNA of each patient (50-100 ng / μl) were denatured at 98 
°C for 5 minutes. After cooling the samples at 25 °C, 0.75 μl of SALSA Probe Mix 
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and 0.75 μl of SALSA MLPA Buffer were added to each tube. The probes were 
hybridized by incubating the samples at 95 °C for 1 minute and at 60 °C for about 
16-20 hours (overnight). Keeping the temperature of the thermal cycler at 54 °C, 
16 μl of the following mix was added to the reaction: 
- 12.5 μl of filtered H2O MilliQ 
- 1.5 μl of Ligase Buffer A 
- 1.5 μl of Ligase Buffer B 
- 0.5 μl of SALSA Ligase-65. 
The ligation of the probes was performed by incubating the reaction at 54 °C for 
15 minutes and then the enzyme was inactivated at 98 ° C for 5 minutes. The 
samples were finally cooled at 20 °C. 
For the subsequent amplification reaction, a mix containing 1.875 μl of filtered 
H2O MilliQ, 0.5 μl of SALSA PCR Primer Mix and 0.125 μl of SALSA 
Polymerase was prepared for each sample. The mix was combined with 10 μl of 
ligation reaction of the previous step and was subjected to the following 
temperature program: 
- 40 cycles of: 
- 90 ° C for 30 seconds 
- 60 ° C for 30 seconds 
- 72 ° C for 1 minute 
- 72 ° C for 20 minutes. 
1.5 μl of each PCR product were combined with 8 μl of formamide (Hi-Di 
Formamide, Applied Biosystems) and 0.5 μl of 500 ROX markers (GeneScan 500 
ROX dye Size Standard, Applied Biosystems) and denatured at 94 °C for 3 
minutes. The samples were subjected to electrophoresis on a capillary sequencer 
3500Dx Genetic Analyzer (Applied Biosystems). The results were visualized and 
analyzed using the Coffalyser v140721.1958 (MRC-Holland) software. 
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3.2. Part II: Β-globine minigene  system for COQ4 IVS4+1G>A 
mutation validation 
To study the possible splicing alteration caused by the new IVS4+1G>A mutation 
in COQ4 gene, it was used an approach based on hybrid minigene. In particular, 
the β-globin minigene previously generated in ours laboratory (Forzan et al., 
2009).  
It was chosen to use β-globin because it is a gene consisting only of three exons 
and therefore easy to amplify into one reaction. The amplified was obtained by 
PCR starting from the human genomic DNA and cloned, using the sites of NheI 
and ApaI restriction enzymes, into the pcDNA 3.1 Hygro vector (Invitrogen), 
which allows the expression of the gene of interest under the guidance of the 
CMV promoter. To facilitate the subsequent cloning steps, in intron 2 of β-globin 
gene has been cloned a polylinker bearing three sites of restriction (XhoI, NotI, 
HindIII), as shown in Figure 20. 
 
 
Figure 20. Graphic representation of the insertion of the β-globin minigene into 
the pcDNA 3.1 Hygro expression vector (Invitrogen). 
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3.2.1. Patient genomic DNA amplification 
The primers used for the amplification of patient genomic DNA have been 
designed by using Primer3 software. Primers contain the restriction sites of XhoI 
and HindIII restriction enzyme (Table 10). 
The DNA region amplified contained the exon adjacent to the mutation in analysis 
with a exon’s upstream and downstream portions of at least 100 bp. 
 
Intron Forwad primer 
 (5’-3’) 
Reverse primer 
 (3’-5’) 
Bp Tm 
(°C) 
4 cttCTCGAGgccagttgtaggtgctccat cttGCGGCCGCctttcctcagggtgtcatgc  341 55 
 
 Table 10 . Primers used for the amplification of the target region of the patient 
genomic DNA, with the respective amplified dimension and melting temperature. 
The PCR reaction is catalyzed by the Phusion DNA-polymerase HF (Thermo 
Scientific): at about 300 ng of DNA were added 5X buffers, 200 μM dNTPs, 5% 
Betaine, 200 nm of each primer and 2.5U of enzyme to the final volume of 50 μl. 
The reactions occurred under the following conditions:  
- 98 ° C for 30 seconds 
- 35 cycles of: 
- 98 °C for 10 seconds  
- 55 °C for 30 seconds 
- 72 °C for 1 minute 
- 72 °C for 7 minutes. 
The presence of products of PCR was verified by 1.5% agarose gel 
electrophoresis. 
 
 
3.2.2. pCR8 and pCDNA3.1 Hygro + vectors 
In this study were used the vector pCR8 TOPO TA (Invitrogen) and the 
mammalian expression vector pCDNA3.1 Hygro
+
 (Invitrogen). 
The vector pCR8 TOPO TA (Invitrogen) is a cloning vector that contains the 
TOPO recognition sites with overhang -TT ends used for the ligation of the 
72 
 
construct of interest, the attL1 and attL2 sites for recombination and the gene that 
confers resistance to spectinomycin for selection in E. coli (Figure). 
The mammalian expression vector pCDNA3.1 Hygro
+
 (Invitrogen) contains a 
human cytomegalovirus immediate-early (CMV) promoter for high-level 
expression in a wide range of mammalian cells, the gene that confers resistance to 
ampicillin for selection in E. coli and the hygromycin resistance gene for selection 
of stable cell lines (Figure 21). 
 
Figure 21. Maps of pCDNA3.1 Hygro
+
 and pCR8 (Invitrogen) vectors. 
 
 
3.2.3. pCR8 TOPO TA cloning 
The amplification products were incubated at 72 ° C for 10 minutes with 1 unit of 
Taq DNA polymerase (Euroclone), the specific buffer 10X and dATPs 0.2 mM, in 
order to reconstruct the overhang poly-A ends. Subsequently  at 4 μl of PCR 
product, 1 μl of salt solution and 1 μl of vector pCR8 TOPO TA (Invitrogen) were 
added. The mixture was incubated for 30 minutes at room temperature. 
Using 3 μl of the ligation reaction, 50 μl of E. coli DH5α bacteria were 
transformed by heat shock:  
- on ice for 30 minutes 
- 42 °C for 45 seconds 
- on ice for 2 minutes.  
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After adding 250 μl of SOC medium, the bacteria were incubated at 37 °C for 1 
hour. They were subsequently plated in LB medium with spectinomycin for 
negative selection, and incubated overnight at 37 °C. 
The colonies that incorporated the vector with the correct orientation insert were 
selected by screening PCR: the 10X buffer, dNTPs 200 μM, 200 nm of the 
primers (primers M13f and Reverse primers were used; Table 14) and 2.5U of the 
enzyme EconoTaq DNA-polymerase (Lucigen) were added to each colony, in a 
final volume of 19 μl. PCR amplification reactions occurred at the following 
conditions: 
- 94 °C for 12 minutes 
- 35 cycles of: 
- 94 °C for 1 minute 
- 55 °C for 1 minute 
- 72 °C for 1 minute 
- 72 °C for 7 minutes. 
The plasmid DNA of the selected colonies was purified with the Spin Miniprep 
Kit (Qiagen) and quantified at the Nanodrop. 
 
 
3.2.4. Miniprep and sequencing 
The bacteria inoculum was carried out in Falcon tubes containing 2 ml of 
LB culture medium and 2 μl of spectinomycin antibiotic. The culture was 
incubated at 37 ° C overnight at 300-400 rpm of oscillation. 
The plasmid DNA was extracted from each inoculums (Miniprep) and then they 
were sequenced by Sanger method: the wild-type clone and the mutated clone 
have been selected. 
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3.2.5. Digestion of pCR8 vector and gel extraction of DNA insert 
To transfer the insert from the pCR8 vector to the β-globin minigene, 6 µg of both 
plasmids (pCR8 and pCDNA3.1 Hygro
+
-β-globin) was digested with HindIII and 
XhoI enzymes able to recognize the restriction sites into the primers sequence.  
A double digestion reaction was performed, incubating at 37 °C for 3 hours and 
then at 80 °C for 20 minutes (to inactivate the enzyme). 
The digestion product was separated by electrophoresis on agarose gel and the 
corresponding size band of the fragment of interest has been cut off. The DNA 
insert was purified with the Qiagen kit and finally it was quantified at the 
Nanodrop. 
 
 
3.2.6. Ligation 
The DNA insert and the pCDNA3.1 Hygro
+
-β-globin vector obtained from the 
digestion reaction were subjected to ligation reaction.  
The amount of insert to be used in the reaction was calculated based on the 
followed  formula:  
Insert (ng) = [6 x construct size] / [7294 x vector (ng)] 
In our study it has been used a relationship 
insert:vector of 6: 1. 
The digestion products were incubated at 16 °C overnight with 1 µl of T4 DNA 
ligase (BioLabs), the specific buffer 10X and ATP 10X. 
Transformation, screening, inoculation and plasmid purification (of the wild-type 
and mutated vectors) were then performed as reported in the previous paragraphs 
with the difference that the spectinomycin has been replaced by ampicillin, whose 
resistance is conferred by the pcDNA3.1 vector. 
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3.2.7. Transient transfection of HEK 293 cells 
1 μg of the wild-type and the mutated COQ4 pCDNA3.1 Hygro+-β-globin was 
used for transfect 7x10
5
 HEK 293 cell cultures (Human Endothelial Kidney that 
do not express β-globin) in 250 μl of Opti-MEM 1X (Gibco) antibiotic and serum-
free medium. 
Within the Falcon tubes were also aliquoted 250 μl of Opti-MEM 1X and 1 μl of 
Lipofectamine 2000 (Invitrogen), a cationic lipid formulation that it is able to 
complex with negative DNA charges facilitating its entry through the cell 
membrane, and were left to room temperature for 20 minutes. 
Finally, the 500 μl obtained were added to each culture and after 6 hours the 
ground was changed replacing Opti-MEM with 2 ml of DMEM 10% FCS 
(Gibco), a medium with 10% serum in which normally cells are grown. 
 
 
3.2.8. RNA extraction from HEK 293 cells 
Total human RNA was extracted and purified using the Trizol kit (Invitrogen). 
Cells were washed with PBS, lysed with 0.05% trypsin and resuspended in 1 ml 
of Trizol. After adding 200 μl of chloroform, the cells were centrifuged at 12,500 
g for 15 minutes. The upper phase containing the RNA was recovered and 
subsequently precipitated in 0.5 ml of isopropanol and incubated at -80 °C 
overnight. 
After centrifugation, the pellet was washed with 70% cold ethanol and 
resuspended in DEPC water (treated with diethyl pyrocarbonate, a powerful 
RNAase inhibitor). 
 
 
3.2.9.  Reverse transcription 
The purified RNA was quantified by spectrophotometer at 260 nm. 
Reverse transcription was performed using the Superscript II Reverse 
Transcriptase II Kit (Invitrogen). 
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Briefly: 100 μg of random primers, 1μl of 0.5 mM dNTPs and DEPC water were 
added to 1 μg of RNA, up to a final volume of 10.5 μl. The reaction mixture was 
incubated at 65 °C for 5 minutes. Subsequently were added: Buffer 5X, DTT 0.01 
M, 40U of RNase OUT and the mixture was incubated at 25 °C for 2 minutes.  
200U of the SuperScript II RT enzyme was added and then the reaction was 
incubated at the following temperature program: 
- 25 °C for 10 minutes 
- 42 °C for 50 minutes 
- 70 °C for 15 minutes. 
 
 
3.2.10. cDNA amplification 
The cDNAs obtained by the RNA reverse transcription was amplified by PCR 
with specific primers for the coding regions of the β-globin gene, in particular the 
primer forward within exon 2 and the reverse primer inside exon 3 of the gene 
(ex2 β-globin forward primer: TCTGTCCACTCCTGATGCTG and ex3 β-globin 
reverse primer: CACTGGTGGGGTGAATTCTT). To confirm the result it has 
been performed also an amplification reaction using the COQ4 exon 4 internal 
primer (ex4 COQ4 forward primer: cttCTCGAGgccagttgtaggtgctccat and ex3 β-
globin reverse primer: CACTGGTGGGGTGAATTCTT). It has been used the 
EconoTaq DNA polymerase (Lucigen)as described in section 3.2.3. 
The thermal cycler has been set as follows: 
- 94 °C for 3 minutes 
- 35 cycles of: 
- 94 °C for 1 minute 
- 55 °C for 1 minute 
- 72 °C for 1 minute 
- 72 °C for 7 minutes. 
The PCR fragments thus obtained were analyzed by electrophoretic 2% agarose 
gel to separate the bands of smaller dimensions.  
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3.3. Part III: Saccharomyces cerevisiae as a model system for 
ASS1 mutation validation 
 
3.3.1.  Microorganisms used in the study 
For the validation and characterization of the ASS1 gene variants identified by 
NGS sequencing were used the bacterial and yeast strains shown in Table 11: 
Strain Genotype Reference 
E. coli ccdB Survival 
F- mcrA ∆(mrr-hsdRMS-mcrBC) 
Φ80lacZ∆M15 ∆lacX74 recA1 
ara∆139 ∆(ara-leu)7697 galU galK 
rpsL (StrR) endA1 nupG tonA::Ptrc-
ccdA 
Invitrogen 
E. coli DH5α 
F- recA1 endA1 hsdR17(rk-, mk+) 
supE44 λ- thi-1 gyrA96 relA1 
Invitrogen 
S. cerevisiae BY4741 
MATa; his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0 
Euroscarf 
S. cerevisiae BY4741 
ΔARG1 
Mat a; his3Δ1; leu2Δ0; met15Δ0; 
ura3Δ0; YOL058w::kanMX4 
Euroscarf 
 
Table 11. Strains and relative genotype of the microorganisms used in the study. 
E. coli ccdB Survival bacteria are competent for transformation and are used for 
negative selection as they are a strain resistant to the ccdB gene, that encodes a 
protein that interacts and inhibits DNA-gyrase, leading to cell death (Bahassi et 
al., 1998). 
The DH5α bacteria are E. coli competent for transformation but not resistant to 
the ccdB gene. 
 
 
3.3.2.  Culture media used in the study 
For the bacterial transformation the liquid medium SOC (Super Optimal Broth 
with Catabolite repression) was used (2% Tryptone, 0.5% yeast extract, 10mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10mM MgSO4 and 20 mM glucose). 
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The LB medium (Triptone 10 g/l, Yeast extract 5 g/l, NaCl 10g/l, pH 7, Agar 
15g/l for solid medium) was used to grow the transformed bacterial cells, added 
the different antibiotics (Table 12) depending on the gene resistance of the vector 
used in the transformation. 
 
Antibiotic Final concentration 
Ampicilline 100 µg/ml 
Chloramphenicol 30 µg/ml 
Spectinomicine 100 µg/ml 
 
Table 12. Antibiotics and their concentration used in the study. 
Different media have also been used for yeast cells. 
YPDA (1% yeast extract, 1% peptone and 2% glucose) is a rich medium used to 
propagate and maintain wild and mutated strains; the corresponding solid medium 
contains 2% of agar. 
SM (0.17% yeast base nitrose without amino acids, 0.5% ammonium sulfate and 
2% glucose or galactose, or 2% raffinate and 0.1% galactose) is a minimal 
medium used to select and maintain yeasts transformed with the different 
constructs, for functional complementary tests and for tests on the requirements 
necessary for the growth of the yeast strain. 
The corresponding solid media contains 2.3% of agar. 
To these minimum medium are added the amino acids for which the yeast strain is 
auxotrophic, at the concentrations reported in Table 13: 
Amino acid µl for plate 
(20 ml) 
µl for ml of 
medium 
Final 
concentration 
Histidine 20 mg/ml 10 0.5 10 mg/L 
Methionine 10 mg/ml 40 2 20 mg/L 
Leucine 20 mg/ml 60 3 60 mg/L 
Arginine 10 mg/ml 40 2 20 mg/L 
Table 13. Amino acids at the concentration used in the study. 
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3.3.3.  pCR8 and pYES.2 vectors 
In this study two different vectors were used: the yeast expression vector pYES.2 
(Invitrogen) present in high number of copies in the cell and the vector pCR8 
TOPO TA (Invitrogen) (see the describtion at the section 3.2.2) for the 
recombination through the Gateway system. 
The pYES.2 vector has the origin of 2μ replication and the pGAL1 promoter that 
allows to modulate the expression of the gene of interest by varying the carbon 
source added to the culture medium: galactose favors high levels of expression, 
the raffinose maintains the basal expression levels and glucose inhibits 
expression. It contains the gene that confers resistance to ampicillin for selection 
in E. coli and the URA3 marker for yeast selection (Figure 22). 
 
Figure 22. Map of pYES.2 (Invitrogen) vector. 
 
 
3.3.4.  Extraction of yeast genomic DNA  
An yeast inoculum in 2 ml of YPDA liquid medium was incubated at 30 °C 
overnight. 
The pellet was recovered by centrifugation and incubated for 10 minutes at -80 
°C. Next were added glass beads and 200 μl of phenol:chloroform:isoamyl 
alcohol in a ratio of 25:24:1. The cells were vortexed 5 times for 1 minute and 
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incubated for 1 minute in ice. After centrifuging for 13 minutes at 13,000 g, 200 
μl of TE buffer were added. 
To recovered the supernatant containing DNA, 400 μl of chloroform were added 
and the mixture was again centrifuged for 10 minutes at 13,000 g. 
The aqueous phase was recovered and 2.5 volumes of 100% cold ethanol were 
added. The mixture was left to precipitate for 30 minutes at -80 °C and then 
centrifuged for 15 minutes at 13,000g. 
The supernatant was removed and the pellet was washed with 1 ml of 70% cold 
ethanol. Centrifuge again for 15 minutes at 13,000g and remove the supernatant. 
The pellet was resuspended in DEPC water, incubated for 10 minutes at 37 ° C 
and then left overnight to hydrate. 
 
 
3.3.5.  RNA extraction from human fibroblasts 
Total human RNA was extracted and purified from a culture of cutaneous control 
fibroblasts using the Trizol kit (Invitrogen). See the describtion at paragraph 3.2.8. 
 
 
3.3.6.  Reverse transcription 
The purified RNA was quantified by spectrophotometer at 260 nm. 
Reverse transcription was performed using the Superscript II Reverse 
Transcriptase II Kit (Invitrogen). See the describtion at paragraph 3.2.9. 
 
 
3.3.7.  Gateway system 
The Gateway technology (Invitrogen) allows to perform an LR recombination 
reaction between an entry clone in which the gene of interest is cloned and a 
destination vector containing the RfA cassette. The advantage of this technique 
lies in allowing a rapid and efficient transfer of a specific DNA sequence in 
several expression vectors, keeping the correct orientation and reading frame. 
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The reaction is catalyzed by the enzyme LR clonase (Invitrogen) which recognizes 
the corresponding attL and attR sequences (Figure 23). 
 
Figure 23. Schematic representation of LR recombination reaction (Invitrogen). 
 
 
3.3.8. Gene amplification and TOPO TA cloning 
ASS1 gene and the corresponding yeast homologue ARG1 gene were amplified 
starting respectively from human retrotranscribed cDNA and yeast genomic DNA. 
The PCR reaction is catalyzed by the Phusion DNA-polymerase HF (Thermo 
Scientific): at about 300 ng of DNA were added 5X buffers, 200 μM dNTPs, 5% 
Betaine, 200 nm of each primer and 2.5U of enzyme to the final volume of 50 μl. 
The reactions occurred under the following conditions:  
- 98 ° C for 30 seconds 
- 35 cycles of: 
- 98 °C for 10 seconds  
- 55 °C for 30 seconds 
- 72 °C for 1 minute 
- 72 °C for 7 minutes. 
Primers used for the amplification of the coding region of the two homologues 
and the respective Tm are shown in Table 14.  
The amplification products were checked by electrophoretic run in 1% agarose 
gel. 
The amplified ASS1 and ARG1 genes were then cloned into the recombination 
vector Gateway pCR8 TOPO TA (Invitrogen). 
The amplification products were incubated at 72 ° C for 10 minutes with 1 unit of 
Taq DNA polymerase (Euroclone), the specific buffer 10X and dATPs 0.2 mM, in 
order to reconstruct the overhang poly-A ends. Subsequently  at 4 μl of PCR 
82 
 
product, 1 μl of salt solution and 1 μl of vector pCR8 TOPO TA (Invitrogen) were 
added. The mixture was incubated for 30 minutes at room temperature. 
Using 3 μl of the ligation reaction, 50 μl of E. coli DH5α bacteria were 
transformed by heat shock:  
- on ice for 30 minutes 
- 42 °C for 45 seconds 
- on ice for 2 minutes.  
After adding 250 μl of SOC medium, the bacteria were incubated at 37 °C for 1 
hour. They were subsequently plated in LB medium with spectinomycin for 
negative selection, and incubated overnight at 37 °C. 
The colonies that incorporated the vector with the correct orientation insert were 
selected by screening PCR: the 10X buffer, dNTPs 200 μM, 200 nm of the 
primers (primers M13f and ASS1_1285r or ARG1_1289r were used; Table 14) 
and 2.5U of the enzyme EconoTaq DNA-polymerase (Lucigen) were added to 
each colony, in a final volume of 19 μl. PCR amplification reactions occurred at 
the following conditions: 
- 94 °C for 12 minutes 
- 35 cycles of: 
- 94 °C for 1 minute 
- 55 °C for 1 minute 
- 72 °C for 1 minute 
- 72 °C for 7 minutes. 
The plasmid DNA of the selected colonies was purified with the Spin Miniprep 
Kit (Qiagen) and quantified at the Nanodrop. 
To verify the correct insertion of the ASS1 and ARG1 genes, a restriction analysis 
was performed. The appropriate enzymes were chosen by consulting the vector 
restriction map (available at www.NEBcutter.com). To 500 ng of plasmid are 
added 10U of digestion enzyme, Buffer 10X, BSA 10X, to a final volume of 10 
μl. The reaction was incubated at 37 °C for 1 hour. 
Subsequently 5 μl of the digestion were loaded on 1% agarose gel. 
The sequences were finally checked by sequencing (BMR Genomics): 500 ng of 
plasmid and 6.4 pmol of each primer were dried at 65 °C. The sequences were 
aligned with the reference ones using the BLAST tool. 
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3.3.9.  Destination vector preparation 
The pYES.2 vector was used as destination vector: for this purpose the RfA 
cassette was inserted into the MCS. 
The vector was linearized by enzymatic digestion and the digestion product was 
purified by electrophoretic run in 1% agarose gel. The restriction enzyme used 
creates overhang ends, so it is necessary to make them blunt by adding 1U of 
Klenow DNA polymerase (Thermo Scientific), the specific 10X buffer and the 
dNTPs. Klenow DNA polymerase (Thermo Scientific) must then be inactivated by 
incubating it at 75 °C for 10 minutes. 
The linearized vector was phosphorylated by incubating it with the SAP enzyme 
(Shrimp Alkaline Phosphatase) and purified through the columns of the Amicon 
Ultra 100K device Kit (Millipore). 
The RfA cassette was ligated into the vector using overnight incubation at 16 °C 
with 1U of the enzyme T4 ligase (Thermo Scientific). The RfA cassette contains 
resistance to chloramphenicol, the toxin coding ccdB gene and it is flanked by the 
attR1 and attR2 recombination sites (Figure 24). 
 
Figura 24. Scheme of the RfA cassette (Invitrogen). 
 
E. coli ccdB bacteria (as described previously) were resistant to the ccdB toxin, 
plated in LB medium to which ampicillin and chloramphenicol were added. 
The presence and the orientation of the RfA cassette in the colonies were screened 
by screening PCR (as described above) using the T7 and ccdBr primers, shown in 
Table 14. 
The plasmid DNA of the selected colonies was purified with the Spin Miniprep 
Kit (Qiagen) and quantified at the Nanodrop. 
The sequences were controlled by sequencing (BMR Genomics). 
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3.3.10.  LR ricombination 
The recombination reaction was performed between the entry clone containing the 
gene of interest and the destination vector with the RfA cassette. 
2 μl of the pCR8_RfA vector (75 ng/μl) were added to 1 μl of pYES.2_ASS1 
vector or to 1  μl  of pYES.2_ARG1 (150 ng / μl) vector. 
5 μl of Buffer TE and 2 μl of enzyme LR clonase (Invitrogen) were then added. 
The reaction mixture was incubated at 25 °C overnight. The reaction was stopped 
by adding 1 μl of proteinase K and incubating  it at 37 °C for 10 minutes. 
2 μl of the recombination reaction were used to transform 50 μl of DH5α bacteria, 
then plated in LB medium containing ampicillin and incubated overnight at 37 °C. 
The plasmid DNA of the selected colonies was purified with the Spin Miniprep 
Kit (Qiagen) and quantified at the Nanodrop. 
The correct integration of the gene of interest in the pYES.2 vector was verified 
by PCR (as described above but by performing an initial denaturation at 94 °C for 
5 minutes) using the primers T7 and ASS1_1285r / ARG1_1289r (Table 14). 
 
 
3.3.11. Site-specific mutagenesis 
The mutants were generated by site-specific mutagenesis of the pCR8_ASS1 
constructs using the Site-Directed Mutagenesis II QuickChange II Kit 
(Stratagene). The primers containing the specific mismatches, designed by the 
Stratagene Primer Design software (www.genomics.agilent.com) are shown in 
Table 14. The amplification reaction was performed by adding to the 10 ng 
plasmid: 125 ng of each primer, 1 μl of dNTPs, the reaction buffer 1X, 2.5U of 
the enzyme PfuUltra H to the final volume of 50 μl. The following conditions 
were used for the PCR amplification reaction: 
- 95 °C for 30 seconds 
- 14 cycles of: 
- 95 ° C for 30 seconds 
- 55 ° C for 1 minute 
- 68 ° C for 9 minutes 
- 68 ° C for 7 minutes. 
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The amplification product was incubated at 37 °C for 2 hours with 10U of the 
restriction enzyme DpnI (Thermo Scientific), which specifically digests the 
methylated and hemimethylated DNA (parental DNA). 
The chemo-competent DH5α bacteria (Invitrogen) were transformed with 5 μl of 
the digestion product and then plated into LB medium containing spectinomycin 
for the positive selection of the transformants that acquired the plasmid. 
The presence of point mutations was confirmed by automatic sequencing after 
amplification with Taq DNA polymerase (Roche) under standard conditions. 
The vectors containing the correct sequences and the desired mutations were 
extracted and purified with the Spin Miniprep Kit (Qiagen). 
The ASS1 gene containing the different missense mutations was subsequently 
transferred to the expression vector in yeast pYES.2 by LR recombination, as 
described in § 2.14.3. 
Primers used in the study (Integrated DNA Technologies) are shown in Table 14: 
Reaction Primer sequence Tm 
ASS1 
amplification 
from cDNA 
hASS_cDNA-27f 
(5’-gaactcacgcctccaatcc-3’)  
64°C hASS_cDNA_1285r 
(5’-gggatctgcaaattgaggag-3’) 
ARG1 
amplification 
from genomic 
DNA 
yARG1-10f 
(5’-gcataaaataatgtctaaggg-3’)  
56°C yARG1_1289r 
(5’-tatcttgaggcgatgaacta-3’) 
Mutagenesis 
G14S 
(5'-ggcctacagtggcagcctggacacctc-3')  
78.0°C G14S_antisense 
(5'-gaggtgtccaggctgccactgtaggcc-3') 
W179R 
(5'-ctcccaagaacccgaggagcatggatgag-3')  
78.81°C W179R_antisense 
(5'-ctcatccatgctcctcgggttcttgggag-3') 
R265H 
(5'-gcatggcgtgggccatattgacatcgtgg-3') 
78.81°C 
R265H_antisense 
(5'-ccacgatgtcaatatggcccacgccatgc-3') 
R304W 
(5'-gccttcaccatggactgggaagtgcgcaaaa-3') 
78.98°C 
R304W_antisense 
(5'-ttttgcgcacttcccagtccatggtgaaggc-3') 
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Table 14. List of used primers. 
 
 
3.3.12.  Yeast transformation 
Yeast cells were transformed by PEG-Lithium acetate method as reported by 
Chen et al. in 1992. 
Yeast cells were allowed to grow overnight at 28 °C in 1.5 ml of YPDA medium. 
The pellet has been recovered  and then 5 μl of denatured carrier DNA (Clontech), 
750 ng of plasmid DNA and 100 μl of transforming solution (40% PEG 4000, 0.2 
M of LiAc at 7.5 pH and 0,1 M of DDT) were added. The cells were resuspended 
by vortex, incubated for 30 minutes at 45 °C and then plated in minimal medium 
Reaction Primer sequence Tm 
Mutagenesis 
G324S 
(5'-gagctggtgtataccagtttctggcacagcc-3’) 
78.98°C 
G324S_antisense 
(5'-ggctgtgccagaaactggtatacaccagctc-3') 
R363L 
(5'-tacatcctcggcctggagtccccactg-3') 
76.0°C 
R363L_antisense 
(5'-cagtggggactccaggccgaggatgta-3') 
G390R 
(5'-agccaactgatgccaccaggttcatcaacatcaat-3') 
78.10°C 
G390R_antisense 
(5'-attgatgttgatgaacctggtggcatcagttggct-3’) 
Validation PCR 
T7f 
(5’-taatacgactcactataggg-3’) 
47.50°C 
pYES.2r 
(5’-ttcggttagagcggatgtgg-3’) 
57.0°C 
M13f 
(5’-gtaaaacgacggccag-3’) 
50.70°C 
M13r 
(5’-caggaaacagctatgac-3’) 
47.0°C 
ASS1_1285r 
(5’-gggatctgcaaattgaggag-3’) 
53.40°C 
ARG1_1289r 
(5’-tatcttgaggcgatgaacta-3’) 
50.30°C 
ccdBf 
(5’- ggtaagcacaaccatgcaga-3’) 
56.0°C 
ccdBr 
(5’- acctgcagactggctgtgta-3’) 
58.0°C 
87 
 
with 2% glucose (SM GLU2% HMLR) to which were added the amino acids for 
which the strain is auxotrophic, but not the amino acid that allows the plasmid 
selection (Uracil for pYES.2). 
The transformed yeasts were propagated for two generations in SM liquid 
medium added with H, M, L, R with 2% galactose in order to induce the 
expression of the ASS1 gene, which is under the control of the pGAL1 promoter. 
 
 
3.3.13.  Phenotypic growth test in plate (Drop test) 
The phenotypic growth analysis was performed starting from steady-state cultures 
of transformed yeasts, in a minimum medium containing 2% galactose and the 
aminoacids for which the strain is auxotrophic, including arginine (SM GAL2% 
HMLR). 
A volume of cells was taken with OD 600 nm of 1, the pellet was washed 2 times 
in 500 μl of H2O milliQ by centrifuging at 5000 g for 5 minutes and then 
resuspended in 1 ml of H2O milliQ. 
5 serial dilutions were made: 10
0
, 10
-1
, 10
-2
, 10
-3
 and 10
-4
. 
5 μl of each dilution were sown in 3 different minimum media:  
- 2% galactose medium (SM GAL2% HML); 
- 2% raffinose medium with 0.1% of galactose, to which were added the 
amino acids for which the strain is auxotrophic but not arginine (SM 
RAF2% -GAL0.1% HML); 
- medium containing arginine as a control (SM GAL2% HMLR).  
The plates were incubated at 28 °C for the time necessary for growth (between 6 
and 10 days). 
 
 
3.3.14.  Extraction of proteins from yeast 
Yeast total proteins were extracted by mechanical lysis and precipitation with 
TCA (trichloroacetic acid). 
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Starting from a steady-state culture in minimal medium containing 2% galactose 
and the amino acids for which the strain is auxotrophic (SM GAL2% HMLR), a 
volume of cells with an OD of 600 nm of 5 was taken.  
The pellet was resuspended in 100 μl of 20% TCA. The mechanical lysis of the 
cells was performed using a vortex after adding a volume of glass beads. After 
adding 500 μl of 5% TCA, the supernatant was transferred into a new eppendorf 
and centrifuge at 14000 rpm for 5 minutes at 4 °C, to obtaining a precipitate 
containing the proteins. The pellet was then resuspended in 200 μl of Laemmli 
buffer (Tris-Cl 0.1 M pH 6.8, SDS 2%, DTT 50 Mm, glycerol 10%, bromophenol 
blue 0.01%). Subsequently 20 μl of 1.5 M Tris at pH 8.8 were added to turn the 
sample to the initial violet color. The sample was denatured by incubating it at 95 
°C for 5 minutes. 
 
 
3.3.15.  Western blot 
Yeast protein extract was separated by electrophoretic run on acrylamide gel 
(Biorad apparatus). 
Then were prepared a stacking gel (4% solution of acrylamide-bis 
acrylamide, 0.1M Tris pH 6.8, 0.1% SDS, 0.1% APS 0.1% and 0.1% TEMED) 
and a running gel (12% solution of acrylamide-bis acrylamide, 0.4 M Tris pH6.8, 
SDS 0.1%, APS 0.1% and 0.05% TEMED). After charging equal amounts of 
protein extract, a constant voltage of 130 V was applied for 90 minutes in the 
presence of the Tris-Glycine-SDS reaction buffer (25 mM Tris, 192 mM glycine, 
0.1% SDS). 
At the end of the run, the samples were transferred onto the PVDF (GE 
Healthcare) membrane by applying a constant voltage of 100 V for 90 minutes in 
the presence of the Tris-Glycine reaction buffer (25 mM Tris, 192 mM glycine, 
10% methanol). 
The membrane was activated by incubating it with methanol for 1 minute and 
then saturated by incubating it for 1 hour with 3 % BSA (bovine serum albumin) 
in Tween-TBS (Tris-HCl 50 mM pH 7.5, NaCl 150 mM, NaN₃ 0.01 % and Tween 
0.1%). 
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Subsequently, the membrane was incubated in overnight agitation at 4 °C 
with the monoclonal primary anti-ASS1 antibody diluted 1:500 in 3% TBA. The 
membrane was washed 3 times with Tween-TBS for 10 minutes and incubated for 
1 hour at room temperature with the immunoperoxidase-conjugated antibody 
diluted in 3% TBA. The signal was detected using the ChemiDocTM XRS
+
 
Molecular Imager apparatus (Biorad) after adding Lite Ablot TURBO reagent 
(Euroclone) which acts as a substrate for peroxidase. 
As a reference for the quantification of proteins, the membrane was also 
incubated with the primary anti-yPorina antibody (Mitoscience) diluted 1:1000 in 
3% TBA and then with the mouse anti-goat secondary antibody (Santa Cruz 
Biotechnology) diluted 1: 2000 in 3% TBA. 
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4. RESULTS AND DISCUSSION 
 
4.1.  Identification of a new renal phenotype associated with 
the m.15170G>A mitochondrial DNA mutation in the MT-
CYB gene  
Nextera XT DNA Library Prep Kit (Illumina) technology is used for the analysis 
of the mitochondrial genome, which is amplified in two superimposed amplicons 
of 9 Kb each. It is a fast and economical system that allows to obtain a high 
coverage and is highly sensitive (i.e. able to detect percentages of heteroplasmy 
up to 1-5%). 
 We studied a patient with a multisystem disorder that presented at age 20 years 
with proteinuria and microhematuria. At age 25 she developed cataracts and 
sensorineural hearing loss. Alport syndrome was suspected and a renal biopsy 
showed a slight increase in mesangial matrix, some scattered areas of fibrosis 
along the interstitial tubule with some infiltrates, tubular atrophy, some 
microcystic formations, and mild thickening of the vascular walls. EM was 
unremarkable ruling out Alport syndrome. Renal function progressively worsened 
and at age 34 she started dialysis. At age 37 she developed hypertrophic 
cardiomyopathy. A brain CT scan was essentially normal. She was evaluated by 
our service at age 38. Physical eamination was unremarkable except for diffuse 
muscle atrophy but she did not complain of cramps or of excersise intolerance. 
In the suspicion of a mitochondrial disorder the entire mtDNA, extracted from 
peripheral white blood cells, was sequenced. The analysis identified the 
m.15170G>A p.Gly142* heteroplasmic nonsense mutation in the MT-CYB gene: 
the mutation affected approximately 22% of mitochondrial genomes (Figure 25). 
PCR-RFLP analysis confirmed the mutation in blood and revealed its presence 
also in DNA extracted from other tissues as hair follicles, buccal cells, and in 
urinary sediment cells (heteroplasmy in these cells was around 60%) (Figure 26). 
The mutation was absent in tissues from the healthy mother and from a control 
individual. 
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Figure 25. Analysis of the patient's entire mtDNA extracted from peripheral blood 
leukocytes using the IGV (Illumina) (A) and mtDNA Variant Analyzer (Illumina) 
software (B). 
B 
A 
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Figure 26. Heteroplasmy levels of the m.15170G>A p.Gly142 * mutation in the 
MT-CYB gene in different tissues of the patient. The analysis was made by PCR-
RFLP amplifying using primers flanking the mutation and digesting with the 
enzyme AcuI (the mutation creates an AcuI site ). The electrophoretic run was 
made using a 12% acrylamide gel, using the 1Kb DNA Ladder marker (Sigma-
Aldrich). 
 
The mutation introduces a premature STOP codon which abolishes translation of 
almost 2/3 of the protein, its pathogenicity is obvious, and accounts for the 
phenotype of the patient. 
This case highlights several important points. Nonsense MT-CYB mutation are 
usually restricted to skeletal muscle and cause exercise intolerance and 
myoglobinuria. Our findings show that they may cause systemic phenotypes 
affecting also the kidney. Interestingly the renal tubule was not affected as in 
other autosomal recessive defects of complex III, but instead we observed 
glomerular involvement, similar to what is seen with the 3243A>G MELAS 
mutation. This is the first defect in a mtDNA protein coding gene associated with 
glomerulopathy. In patients with glomerular involvment, in the suspicion of a 
mitochondrial disorder, the analysis should not be restricted to the recurring 
m.3243A>G mutation but it should include the entire mtDNA sequence. 
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4.2. Comparative analysis of NGS methods TruSeq Custom 
Amplicon Low Input Library Prep Kit (Illumina) and  HaloPlex 
HS Target Enrichment System (Agilent Technologies) used to 
study human genomic DNA 
In the Clinical Genetics Unit of the Hospital of Padua the NGS technology is used 
for the diagnosis of various rare genetic diseases. A disease is considered to be 
rare when it affects no more than one individual per 2000 inhabitants. 
The main diseases analyzed are: metabolic diseases (from neonatal and non-
neonatal screening), mitochondrial diseases from nuclear genes and mitochondrial 
DNA, RASopathies, neurofibromatosis type 1 and type 2, schwannomatosis, 
Marfan syndrome and related syndromes, long QT syndrome and related 
syndromes, craniofacial anomalies, peripheral neuropathies, spinal muscular 
atrophy, hypertrophic cardiomyopathies, deafness (syndromic and non), 
porphyrias. 
The laboratory has a MiSeqDx sequencer (Illumina), optimized for diagnostic 
applications, a flexible and convenient system for small runs. Unlike the Sanger 
method, NGS technology allows a high degree of multiplexing, it is able to 
analyze millions of DNA fragments sequences of different patients in a single run, 
realizing a clear reduction in costs and times needed to generate sequence data. 
The sequencing technology that the MiSeqDx tool uses and which is currently 
adopted by most NGS platforms is known as sequencing by synthesis (SBS); it 
uses dNTPs labeled with four different fluorochromes and a reversible chain 
termination chemistry. 
The NGS technologies TruSeq Custom Amplicon Sequencing Protocols Low Input 
Library Prep Kit (Illumina) and HaloPlex HS Target Enrichment Systems (Agilent 
Technologies) are two amplicon-based methods based on the generation of DNA 
amplicons from small amounts of the patient's genomic DNA, using customized 
oligonucleotides as primers for the amplification. 
For the comparison between the two methods the following parameters were 
considered. 
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Coverage:  The HaloPlex HS Target Enrichment System (Agilent Technologies) 
protocol provides greater coverage, in fact the percentage of gene regions with a 
coverage higher than 20X is greater than the TruSeq Custom Amplicon Low Input 
Library Prep Kit (Illumina).  
The main difference between the two methods consists in the approach used to 
generate libraries of DNA fragments.  
TruSeq Custom Amplicon Low Input Library Prep Kit (Illumina) uses a pool of 
custom probes to capture and enrich the target regions of interest, while the 
HaloPlex HS Target Enrichment System (Agilent Technologies) technology 
provides a previous step of enzymatic digestion with 8 different pairs of 
restriction enzymes that increase the heterogeneity of the generated DNA 
fragments. This heterogeneity ensures greater coverage, overcoming the problem 
of mutations located in critical positions (e.g. the binding sites of the custom 
probes). That cause the loss of coverage of that specific target region. Allele 
dropout alone does not explain loss of coverage. The problem is intrinsic in the 
amplification protocol. 
With HaloPlex HS Target Enrichment System (Agilent Technologies) each 
nucleotide is covered by multiple amplicons, with a different beginning and end, 
and if a mutation is located in a restriction site, it alters only few fragments (one 
or two) but not all the others; with TruSeq Custom Amplicon Low Input Library 
Prep Kit (Illumina) each base is covered by a single type of amplicon and if a 
mutation is located in the binding site of the primer the result is the complete 
dropout of the target region (the proportion of target regions with coverage less 
than 20X is 3-4 times higher than Agilent Technology method) (Table 15).  
 
  
Actual coverage 
(% of coding region) 
Missed Targets 
Gene Disease 
HaloPlex HS 
system 
TruSeq 
system 
HaloPlex HS 
system 
TruSeq 
system 
GAA Pompe disease 100 96 0 2 
GBA Gaucher disease 99.6 97 0 2* 
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Actual coverage 
(% of coding region) 
Missed Targets 
Gene Disease 
HaloPlex HS 
system 
TruSeq 
system 
HaloPlex HS 
system 
TruSeq 
system 
CPOX 
Coproporphyria 
Harderoporphyria 
99.3 94 0 1 
NPC1 
Niemann-Pick 
disease 
100 97 0 2 
CFTR Cystic fibrosis 99.3 93 1 4 
ATP7B Wilson disease 100 96 0 2 
NF1 Neurofibromatosis 99.1 96 1 3* 
IDUA MPS1 99.5 98.5 0 1 
Table 15. Comparative analysis of NGS methods TruSeq Custom Amplicon Low 
Input Library Prep Kit (Illumina) and  HaloPlex HS Target Enrichment System 
(Agilent Technologies) about the number of proportion of target regions with 
coverage less than 20X. 
Results variability: TruSeq Custom Amplicon Low Input Library Prep Kit 
(Illumina) demonstrated a marked variability in the performance between one 
sequencing run and another, while for the HaloPlex HS Target Enrichment System 
(Agilent Technologies) panels the results obtained are highly reproducible. 
 
Pseudogenes and false positives (mutations not confirmed by Sanger 
sequencing) discrimination: NF1 gene mutations cause the Neurofibromatosis 
type 1 disease, an autosomal dominant disease whose main feature is the 
predisposition to the development of tumors involving the peripheral and central 
nervous system. NF1 analysis has shown that the major problems of pseudogenes 
discrimination is obtained using the TruSeq Custom Amplicon Low Input Library 
Prep Kit (Illumina). In patients, a large number of variants are identified in the 
NF1 gene (most of them are false positives) due mainly to the presence in the 
human genome of pseudogenes that show more than 90% of identity with the 
sequence of NF1 gene.  
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Amplicon generation: A further limitation of the Truseq technology is the 
maximum size of the panels. Illumina recommends not to use panels larger than 
500-600 amplicons because there is a drop in the performance for larger designs.  
This corresponds to 25-30 genes of average size (10 exons gene - 2 
amplicons/exon). Instead, the Haloplex technology allows to design panels of 
more than 100 genes (for the same price of a 25-30 gene panel).  
 
For all these reasons since 2017, we have employed  only the HaloPlex HS Target 
Enrichment System (Agilent Technologies) panels. 
We have optimized these panels for the novel V2 Reagent kits. Currently we are 
using two sets of panels "small" and "large".  
Small panels comprise on average 30-40 genes, for a total sequenceable design of 
about 250-260 kb. These panels allow to run 10 patients on a V2 micro kit (Table) 
and 30 patients on a standard kit with an average coverage of at least 500x. 
Such high coverage is essential to ensure that >98% of the design has at least 20x 
coverage.  Large panels include 90-120 genes with a total sequenceable design of 
about 750-820 kb. These panels allow to run 10 patients on a standard kit (Table 
16) with a similar performance.  
The designs covered more than 99.7% of the target region and more than 98% of 
patients had less than 2% of the analyzable target with coverage inferior to 20x 
(on average this value was 99%).  
It is important to note different panels can be included in the same run. 
Reagent kit N° of reads N° of cycles Output 
MiSeq Reagent 
Standard Kit V2 
15 M 300 4.5 Gb 
MiSeq Reagent 
Micro Kit V2 
4 M 300 1.2 Gb 
 
Table 16. MiSeq Reagent Kit V2 (Illumina) commercially available with relative 
output values. 
Each panel includes common disease genes and rarer disease genes, even of 
unrelated diseases, allowing to provide the results also of the most rare diagnoses 
quickly.  
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As of September 2018 this system covers more than 1300 genes and we have 
studied more than 1700 patients (considering only those analyzed with Haloplex 
assays). 
Until January 2018 all mutations were confirmed by Sanger sequencing. However 
we realized that we ha no false positive results (provided that coverage and 
quality of the sequences were adequate) whereas we had 5 cases of false negative 
results on Sanger. All these cases were due to allele dropout because of rare 
polymorphisms on the PCR primer binding sites, which could not be avoided due 
to insufficient data in the different variant database (EVS, ExAC, and in parto also 
GnomAD). For these reasons, we are stopped confirming by Sanger sequencing 
those variants that have satisfactory quality parameters. 
 
 
4.3.  Neonatal metabolic screening by HaloPlex HS Target 
Enrichment System (Agilent Technologies) panels 
Among all patient referred to our center to confirm the results of neonatal 
metabolic screening, we selected for this work 106 patients who were found 
positive for either Mucopolysaccharidosis type I (MPS I), Biotinidase Deficiency, 
or Phenylketonuria (PKU).  
 
IDUA deficiency 
Very little data is available in the literature on the molecular characterization of 
patients identified by neonatal screening. Some of our preliminary data were 
recently published (Burlina et al, 2018). We have shown that the majority of 
positive cases actually present pseudodeficiency, a situation caused by the 
presence of alleles with reduced IDUA enzymatic activity, but still compatible 
with a normal phenotype. Standard biochemical assays are usually not sensitive 
enough to discriminate these cases from true IDUA deficiency (especially from 
the mild forms). Several common pseudodeficiency alleles have been reported: 
p.Ala79Thr, p.His82Gln, and p.Asp223Asn (Pollard et al, 2017). It is important to 
correctly classify these individuals because they do not need enzyme replacement 
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therapy. We now present our complete series of patients. NGS sequencing of the 
IDUA gene in 17 patients (Table 17) revealed that 13 of them (76%) had a 
genotype compatible with pseudodeficiency (they carried at least one 
polymorphism associated with pseudodeficiency), 2 harbored known pathogenic 
mutations and therefore were diagnosed with MPS1 (11%), 1 patient had a novel 
missense change in the homozygous state which was classified as “variant of 
unknown significance”, 1 had a single heterozygous pathogenic mutation, and in 1 
patient no mutations were detected. In the 13 pseudodeficiency patients (total 26 
alleles) we found 16 p.Ala79Thr alleles (61%) in 5 cases in the homozygous state, 
in 2 in trans with a pathogenic IDUA mutation, in 2 in trans with a VUS, and in 2 
cases in trans with another pseudodeficiency polymorphism. Virtually all cases 
harboring the p.Ala79Thr variant were of African origin, consistent with the high 
MAF (4%) in this population (in Europeans MAF is less tha 1:15000). 
Interestingly, patients 7a and 7b are dizygotic twins who both tested positive for 
IDUA deficiency at neonatal screening but had discordant genotypes. Both 
harbored the p.Ala79Thr polymorphism in the heterozygous state, patient 7a had 
the p.(Leu237Phe) VUS, while her sister had the p.Asp223Asn pseudodeficiency 
allele. After identification of patient 7a, her sister was screened by Sanger 
sequencing, that detected only the p.Ala79Thr variant. Because of the clear 
biochemical phenotype patient 7b was studied by NGS and the second allele was 
identified. Given the high frequency in the population (especially of African 
origin) of these pseudodeficiency alleles, relatives of pseudodeficiency cases 
found positive at newborn screening should be screened for mutation in the whole 
gene since they could harbor a different genotype than the index case. 
Providing a clear diagnosis is indispensable to reassure the parents in case of 
pseudodeficiency, and to institute enzyme replacement therapy in cases with a 
definite diagnosis of MPS1. Overall, our NGS protocol allowed to obtain a 
definite result in 15/17 patients (88%), while in 2 (12%) the analysis was 
inconclusive. Considering that the cost of NGS is relatively low (less than 
120€/sample in terms of reagents) it represents a convenient diagnostic technique 
for patients identified by neonatal screening and is essential to avoid unnecessary 
treatments (which are very expensive) in individuals with pseudodeficiency. 
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Pt NGS analysis results Hom/Het Clinical significance 
1 
c.235G>A p.Ala79Thr + 
c.1081G>A p.Ala361Thr in cis 
het pseudodeficiency 
c.1743C>G p.(Tyr581*) het pathogenic 
2 c.235G>A p.Ala79Thr + 
c.1081G>A p.Ala361Thr in cis 
hom pseudodeficiency 
3 
c.46_57del p.(Ser16_Ala19del) het pathogenic 
c.246C>G p.His82Gln het pseudodeficiency 
4 c.235G>A p.Ala79Thr hom pseudodeficiency 
5 c.235G>A p.Ala79Thr hom pseudodeficiency 
6 c.1598C>G p.Pro533Arg hom pathogenic 
7a 
c.235G>A p.Ala79Thr het pseudodeficiency 
c.709C>T p.(Leu237Phe) het uncertain significance 
7b  
c.235G>A  p.Ala79Thr 
het 
 
pseudodeficiency 
 
c.667G>A p.Asp223Asn het pseudodeficiency 
8 c.1577T>C p.(Leu526Pro) hom 
uncertain significance 
likely pseudodeficiency (high MAF) 
9 c.235G>A p.Ala79Thr hom pseudodeficiency 
10 
c.46_57del p.(Ser16_Ala19del) het pathogenic 
c.603C>G p.(Tyr201*) het pathogenic 
11 
c.1501T>C p.(Phe501Leu) het uncertain significance 
c.235G>A p.Ala79Thr het pseudodeficiency 
12 c.1882C>G  p.(Arg628Gly) hom uncertain significance 
13 c.235G>A p.Ala79Thr hom pseudodeficiency 
14 c.235G>A p.Ala79Thr hom pseudodeficiency 
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Pt NGS analysis results Hom/Het Clinical significance 
15 
c.235G>A p.Ala79Thr het pseudodeficiency 
c.667G>A p.Asp223Asn het pseudodeficiency 
16 No mutations detected   
17 c.1598C>G p.Pro533Arg 
no second mutation identified 
het pathogenic 
Table 17. List of patients (Pt) positive at neonatal metabolic screening for 
Mucopolysaccharidosis type I. Patients marked in grey harbored known 
pathogenic mutations and therefore were diagnosed with MPS1; in patient marked 
in pink no mutations were detected; patients marked in yellow had a novel 
missense change in the homozygous state or had a single heterozygous pathogenic 
mutation. 
 
BTD deficiency 
NGS analysis of BTD gene of 32 patients showed that 5 patients (16%) had a 
genotype compatible with the classical form of the disease. 21 (68%) had partial 
deficiency (they were compound heterozygotes for a severe mutation and for the 
mild variant p.Asp444His); 3 patients were heterozygotes for a single 
pathogenetic mutation, 1 was homozygote for p.Asp444His, and in 1 patient two 
variants were found (p.Ala171Thr and p.Asp444His) but their phase could not be 
confirmed (Table 18). In 1 patient no variants were detected. 
All patients with a severe deficiency were correctly genotyped, as well as the 
majority of those with partial deficiency. We do not have follow up data for all 
our cases but at least in two among those with an inconclusive analysis the 
deficiency was not confirmed at follow up.   
Most of the variants are located in exon 4 of the gene therefore we considered the 
possibility of performing as initial screening for these patients Sanger sequencing 
of exon 4. This would have allowed a correct diagnosis in 18/32 patients (56%). 
However we found the p.Asp444His variant in cis with a pathogenic mutation in 
the 5’ region of the gene in at least 2 different complex alleles, in a total of 3 
patients, who would have been incorrectly diagnosed using this strategy. For this 
reason we rejected this strategy, and mutation screening is still performed by 
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NGS. Identifying the patient’s genotype is essential for a correct treatment. We 
are currently treating only those patients with 2 severe mutations.   
 
Pt NGS analysis results Hom/Het 
Clinical 
significance 
BTD 
deficiency 
1 
c.1368A>C p.Gln456His het pathogenic 
severe 
c.1439G>A p.(Gly480Glu) het pathogenic 
2 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1595C>T  p.(Thr532Met) 
 
het pathogenic 
3 
c.278A>G p.Tyr93Cys het pathogenic 
partial 
c.1330G>C p.Asp444His het polymorphism 
4 c.1330G>C p.Asp444His hom polymorphism partial 
5 
[c.133G>A +c.980dup] [p.Gly45Arg 
+ p.Asn327Lysfs*27] hetero 
het pathogenic 
partial 
c.1330G>C p.Asp444His het polymorphism 
6 
c.511G>A p.Ala171Thr het pathogenic 
partial 
c.1330G>C p.Asp444His (phase 
unknown) 
het polymorphism 
7 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His  het pathogenic 
8 No mutations detected   partial 
9 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His het pathogenic 
10 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His het pathogenic 
11 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His het pathogenic 
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Pt NGS analysis results Hom/Het 
Clinical 
significance 
BTD 
deficiency 
12 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His het pathogenic 
13 c.631C>T  p.(Arg211Cys) 
no second mutation identified 
het pathogenic partial 
14 
c.98_104delinsTCC p.Cys33Phefs*36 het pathogenic 
partial 
c.1330G>C p.Asp444His het polymorphism 
15 c.98_104delinsTCC p.Cys33Phefs*36 
no second mutation identified 
het pathogenic partial 
16 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1466A>G p.(Asn489Ser) 
 
het pathogenic 
17 
c.382T>G p.(Phe128Val) het pathogenic 
partial 
c.1330G>C p.Asp444His het polymorphism 
18 
c.1368A>C p.Gln456His het pathogenic 
severe 
c.1489C>T p.(Pro497Ser) het pathogenic 
19 
c.[1024delG ; 1330G>C] 
[p.Val442Serfs*59; p.Asp444His] 
het 
 
pathogenic 
severe 
c.1368A>C p.Gln456His het pathogenic 
20  
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His het pathogenic 
21 
c.594_596delCGT p.Val199del het pathogenic 
partial 
c.1330G>C p.Asp444His het polymorphism 
22 c.1595C>T p.(Thr532Met) 
no second mutation identified 
het pathogenic 
partial 
23 c.1368A>C p.Gln456His hom pathogenic 
severe 
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Pt NGS analysis results Hom/Het 
Clinical 
significance 
BTD 
deficiency 
24 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His het pathogenic 
25 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His het pathogenic 
26 
c.[511G>A ; 1330G>C] 
p.[Ala171Thr; Asp444His] 
het pathogenic 
partial 
c.1330G>C p.Asp444His het polymorphism 
27 
c.98_104delinsTCC p.Cys33Phefs*36 het pathogenic 
partial 
c.1330G>C p.Asp444His het polymorphism 
28 
c.98_104delinsTCC p.Cys33Phefs*36 het pathogenic 
partial 
c.1330G>C p.Asp444His het polymorphism 
29 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His het pathogenic 
30 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His het pathogenic 
31 
c.334G>A  p.Glu112Lys het pathogenic 
severe 
c.515A>G  p.Asn172Ser het pathogenic 
32 
c.1330G>C p.Asp444His het polymorphism 
partial 
c.1368A>C p.Gln456His het pathogenic 
Table 18. List of patients (Pt) positive for neonatal metabolic screening for 
Biotinidase Deficiency. Patients marked in grey harbored known pathogenic 
mutations and therefore were diagnosed with BTD deficiency; patients marked in 
yellow had a single heterozygous pathogenic mutation or had two variants but 
their phase could not be confirmed; in patient marked in pink no mutations were 
detected. 
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PAH deficiency 
The NGS sequencing protocol for the PAH gene could not adequately cover exon 
7 of the gene, therefore all patients with a single (or without) mutations were also 
analysed by Sanger sequencing of this exon. We studied a total of 57 patients 
(Table 19).  
Fortythree patients (75%) had two mutarions (8 novel mutations). All novel 
mutations were considered likely pathogenic based on MAF, conservations, and 
molecular modelling data.  
Eleven patients (19%) carried only one mutation in heterozygous state.  Eight (for 
the other 3 no adequate DNA was available) of them were also studied by MLPA 
analysis: 2 are heterozygous for the exon 3 deletion while in the other 6 no 
deletions were found. It is important to note that we found one patient with a 
homozygous deletion of exon 3, confirmed by MLPA, indicating that such 
rearrangements are not rare in our population.  
In 2 patients no variants were detected and they were also negative for MLPA 
analysis. 
Pt 
NGS analysis 
results 
Region with 
coverage <20X 
Hom/Het 
Clinical 
significance 
MLPA 
1 
No mutations 
detected 
No mutations 
detected 
  negative 
2 
c.898G>T 
p.Ala300Ser 
 het pathogenic  
c.1208C>T 
p.Ala403Val 
 het pathogenic  
3 
c.824C>G 
p.(Pro275Arg) 
 het 
likely 
pathogenic 
 
c.1222C>T 
p.Arg408Trp 
 het pathogenic  
4 
c.168+5G>C  het pathogenic 
negative 
 no second mutation 
identified 
  
5 
c.143T>C 
p.Leu48Ser 
 hom pathogenic  
6 
c.842C>T 
p.Pro281Leu 
 het pathogenic 
exon 3 
deletion 
(het)  
no second mutation 
identified 
  
7 
c.1208C>T 
p.Ala403Val 
 het pathogenic  
c.1315+1G>A  het pathogenic  
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Pt 
NGS analysis 
results 
Region with 
coverage <20X 
Hom/Het 
Clinical 
significance 
MLPA 
8 
c.898G>T 
p.Ala300Ser 
 het pathogenic no adequate 
DNA 
 
no second mutation 
identified 
  
9 
 
c.734T>C 
p.Val245Ala 
het pathogenic  
 
c.755G>A 
p.(Arg252Gln) 
het pathogenic  
10 
c.526C>T 
p.(Arg176*) 
 het pathogenic  
c.898G>T 
p.Ala300Ser 
 het pathogenic  
11 
c.1163T>C 
p.(Val388Ala) 
 hom 
likely 
pathogenic 
 
12 
c.1243G>A 
p.(Asp415Asn) 
 het pathogenic 
negative 
 
no second mutation 
identified 
  
13 
c.1315+1G>A  het pathogenic 
negative 
 
no second mutation 
identified 
  
14 
c.473G>A 
p.Arg158Gln 
 het pathogenic  
c.526C>T 
p.(Arg176*) 
 het pathogenic  
15 
c.842+3G>C  het pathogenic  
c.1208C>T 
p.Ala403Val 
 het pathogenic  
16 
c.473G>A 
p.Arg158Gln 
 het pathogenic  
c.1315+1G>A  het pathogenic  
17 
c.1208C>T 
p.Ala403Val 
 het pathogenic  
 c.1066-6 G>A het 
likely 
pathogenic 
 
18 
c.842+3 G>C  het pathogenic  
c.898G>T 
p.Ala300Ser 
 het pathogenic  
19 
c.143T>C 
p.Leu48Ser 
 het pathogenic  
c.1223G>A 
p.Arg408Gln 
 het pathogenic  
20 c.1315+1G>A  hom pathogenic  
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Pt 
NGS analysis 
results 
Region with 
coverage <20X 
Hom/Het 
Clinical 
significance 
MLPA 
21 
c.842C>T 
p.Pro281Leu 
 het pathogenic  
c.1208C>T 
p.Ala403Val 
 het pathogenic  
22 
c.473G>A 
p.Arg158Gln 
 hom pathogenic  
23 
c.782G>A 
p.Arg261Gln 
 het pathogenic  
 
c.734T>C 
p.Val245Ala 
het pathogenic  
24 
exon 3  
deletion 
 hom pathogenic 
exon 3 
deletion 
25 
c.1139C>T 
p.Thr380Met 
 het pathogenic 
negative 
 
no second mutation 
identified 
  
26 
c.506G>A 
p.(Arg169His) 
 het 
likely 
pathogenic negative 
 
no second mutation 
identified 
  
27 
c.1222C>T 
p.Arg408Trp 
 het pathogenic  
c.1315+1G>A  het pathogenic  
28 
c.632C>T 
p.(Pro211Leu) 
 hom 
likely 
pathogenic 
 
29 
c.782G>A 
p.Arg261Gln 
 het pathogenic  
c.842C>T 
p.Pro281Leu 
 het pathogenic  
30 
c.1089del 
p.(Lys363Asnfs*37) 
 het pathogenic  
c.1315+1G>A  het pathogenic  
31 
c.863T>G 
p.(Ile288Trp) 
 het 
likely 
pathogenic 
 
c.1315+1G>A  het pathogenic  
32 
c.842C>T 
p.Pro281Leu 
 het pathogenic  
c.898G>T 
p.Ala300Ser 
 het pathogenic  
33 
c.434A>T 
p.Asp145Val 
 het pathogenic  
c.1054delC 
p.(Gly352Valfs*48) 
 het pathogenic  
34 
c.842+3G>C  het pathogenic 
negative 
 
no second mutation 
identified 
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Pt 
NGS analysis 
results 
Region with 
coverage <20X 
Hom/Het 
Clinical 
significance 
MLPA 
35 
c.473G>A 
p.Arg158Gln 
 het pathogenic  
c.1315+1G>A  het pathogenic  
36 
 
c.734T>C 
p.Val245Ala 
het pathogenic  
c.1208C>T 
p.Ala403Val 
 het pathogenic  
37 
c.143T>C 
p.Leu48Ser 
 het pathogenic  
c.1159T>C 
p.(Tyr387His) 
 het 
likely 
pathogenic 
 
38 
c.673C>A 
p.(Pro225Thr) 
 het pathogenic  
c.764T>C 
p.(Leu255Ser) 
 het pathogenic  
39 
No mutations 
detected 
No mutations 
detected 
  negative 
40 
c.529G>A 
p.Val177Met 
 het pathogenic  
c.1222C>T 
p.Arg408Trp 
 het pathogenic  
41 
c.194T>A 
p.(Ile65Asn) 
 het 
likely 
pathogenic 
 
c.1045T>C 
p.(Ser349Pro) 
 het pathogenic  
42 
c.842C>T 
p.Pro281Leu 
 het pathogenic 
exon 3 
deletion 
(het)  
no second mutation 
identified 
  
43 
c.782G>A 
p.Arg261Gln 
 het pathogenic  
c.1208C>T 
p.Ala403Val 
 het pathogenic  
44 
 
c.734T>C 
p.Val245Ala 
het pathogenic  
c.1208C>T 
p.Ala403Val 
 het pathogenic  
45 
c.1208C>T 
p.Ala403Val 
 hom pathogenic  
46 
c.284_286delTCA 
p.(Ile95del) 
 het pathogenic  
c.505C>T 
p.(Arg169Cys) 
 het 
likely 
pathogenic 
 
47 
c.473G>A 
p.Arg158Gln 
 het pathogenic  
c.898G>T 
p.Ala300Ser 
 het pathogenic  
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Pt 
NGS analysis 
results 
Region with 
coverage <20X 
Hom/Het 
Clinical 
significance 
MLPA 
48 
c.782G>A 
p.Arg261Gln 
 het pathogenic  
 
c.734T>C 
p.Val245Ala 
het pathogenic  
49 
c.782G>A 
p.Arg261Gln 
 het pathogenic no adequate 
DNA 
 
no second mutation 
identified 
  
50 
c.143T>C 
p.Leu48Ser 
 hom pathogenic  
51 
c.898G>T 
p.Ala300Ser 
 het pathogenic no adequate 
DNA 
 
no second mutation 
identified 
  
52 
c.842C>T 
p.Pro281Leu 
 het pathogenic  
c.1208C>T 
p.Ala403Val 
 het pathogenic  
53 
c.158G>A 
p.(Arg53His) 
 het 
likely 
pathogenic 
 
c.1055delG 
p.(Gly352Valfs*48) 
 het pathogenic  
54 
c.1222C>T 
p.Arg408Trp 
 hom pathogenic  
55 
c.1222C>T 
p.Arg408Trp 
 hom pathogenic  
56 
c.158G>A 
p.(Arg53His) 
 het 
likely 
pathogenic 
 
c.782G>A 
p.Arg261Gln 
 het pathogenic  
57 
c.158G>A 
p.(Arg53His) 
 het 
likely 
pathogenic 
 
c.611A>G 
p.(Tyr204Cys) 
 het pathogenic  
Table 19. List of patients (Pt) positive for neonatal metabolic screening for 
Phenylketonuria. Patients marked in grey were diagnosed with PKU; patients 
marked in yellow had a single heterozygous pathogenic mutation; in patient 
marked in pink no mutations were detected. Novel mutations are reported in red. 
 
We plan to complete the MLPA analysis in the remaining patients and to analyse 
cDNA in all negative/single mutation patients.  
We are still gathering clinical data, in particular phenylalanine levels at neonatal 
screening and during follow up. This will allow to establish an algorhythm for 
those patients lacking a molecular diagnosis.  
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4.4. Identification of the IVS4+1G>A new mutation in the 
COQ4 mitochondrial nuclear gene using HaloPlex HS 
Target Enrichment System (Agilent Technologies) technology 
and its validation by hybrid minigene system 
Since several years the Clinical Genetics Unit invests in the study of the 
molecular mechanisms involved in the coenzyme Q biosynthesis pathway and in 
the characterization of the new mutations identified in patients with coenzyme Q 
deficiency syndrome. 
Using the NGS sequencing method HaloPlex HS Target Enrichment System 
(Agilent Technologies) it was identified a new COQ4 gene mutation that 
involving the first nucleotide after exon 4 of the gene.  
To verify the possible impact of that nucleotide variation, it was first analyzed by 
a predictive bioinformatics software able to predict the probability of variant to 
cause alterations in the splicing mechanism.  
The software used they were Human Splicing Finder (www.umd.be/HSF3) and 
Mutation Taster (www.mutationtaster.org). Bioinformatics analysis predicted an 
alteration of splicing. 
To validate the pathogenicity of  IVS4+1G>A variant with uncertain significance 
has been amplified by PCR the genomic DNA of the patient (a fragment 
comprising the exon of the COQ4 gene with the mutation  and a portion of at least 
100 nucleotides of the flanking intronic regions). The product of PCR was 
subsequently cloned into the minigene vector at the level of the β-globin intron 2 
(Figure 27).  
After verified by direct sequencing the correctness of the constructs, the selected 
plasmids (one wild-type, one mutated) were used to transfect HEK 293 cells. 
From the latter it was extracted the total RNA that has been retrotranscribed in 
cDNA and amplified using specific primers. The products of amplification were 
then separated and displayed on agarose gel at 2%. 
From the electrophoretic run it emerged that the wild-type minigene expressed in 
HEK 293 cells it determines a correct splicing, while the expression of the 
mutated minigene produces the same band of the wild-type construct and a 
smaller one (Figure 28). 
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Figure 27. IVS4+1G>A mutation cloning scheme. 
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Figure 28. 2% agarose gel electrophoresis analysis. [A] Amplification performed 
using β-globine exon 2 forward primer and β-globine exon 3 reverse primer. The 
band of the wild-type construct (WT) has dimensions equal to 505 bp, the band of 
the mutated (MUT) construct loses about 100 nucleotides of the exon 4 
downstream of the mutation and the band of the empty vector is 284 bases. [B] To 
confirm the result it has been performed also an amplification using COQ4 exon 4 
forward primer and β-globine exon 3 reverse primer. The band of the wild-type 
construct (WT) has dimensions equal to 250 bp while the band of the mutated 
(MUT) construct loses about 100 nucleotides. 
This result suggests that this variant behaves like a hypomorph allele as it allows 
to produce part of the wild-type transcript. 
The result obtained with the minigene shows that the mutation causes the 
activation of a cryptic splicing site of the exon 4 and agrees with what is 
hypothesized through the prediction software. 
The hybrid-minigene technique used in this study proved to be an effective and 
relatively simple method for the validation of variants potentially capable of 
altering splicing, in the absence of RNA of the patient.  
On the other hand this technique shows some limitations given by the fact that 
requires the use of an artificial hybrid gene as a point of departure and that some 
anomalies in splicing could be tissue-specific. These problems are actually partly 
solvable: in the first case it is the technique itself that allows to evaluate the 
correct construction of the artificial hybrid gene through the comparison with the 
wild-type construct (if this is correctly processed it means in fact that the 
minigene respects all the necessary regulatory elements to the spliceosoma for a 
B 
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correct maturation of the transcript and that the alterations detected in the mutated 
construct are attributable exclusively to the presence of the mutation). Regarding 
instead the possible tissue-specific expression, it is possible to use for the analysis 
the cell lines derived from tissues in which the mutation exerts its pathogenic 
effects more.  
 
 
4.5. Saccharomyces cerevisiae as a model for the validation of 
ASS1 gene mutations identified in patients with 
citrullinemia type I 
As mentioned previously, we designed a HaloPlex HS Target Enrichment System 
(Agilent Technologies) panel for the analysis of the genes involved in hereditary 
metabolic diseases, including also urea cycle diseases. 
Previous studies (Trevisson et al., 2009; Doimo et al., 2012) have revealed how 
the yeast complementation allows the evaluation of residual activity of the mutant 
forms of the enzyme argininosuccinate lyase, belonging to the urea cycle: for this 
reason we have decided to apply the same method also for the identification of 
residual activity of the ASS1 mutants, in order to establish possible genotype-
phenotype correlations. 
S. cerevisiae model system was used to verified that the heterologous expression 
of ASS1 human gene was able to correct the growth defect in arginine-free 
medium of a yeast strain bearing a deletion of the corresponding homologue gene 
ARG1 (ΔARG1). 
Subsequently, various missense mutations (G14S, W179R, R265H, R304W, 
G324S, R363L and G390R) were introduced in ASS1 human gene by site-specific 
mutagenesis. The ability of the various ASS1 mutant alleles to restore the growth 
of the ΔARG1 yeast strain was then analyzed with functional complementary 
experiments, testing growth in selective medium under different conditions of 
expression. 
Table 20 shows the genotype of patients taken from literature with the mutations 
analyzed and the corresponding clinical picture. 
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Patient Genotype Clinic features 
Activity 
% ASS1 
Reference 
1 G14S/G324S asymptomatic n.a. Haberle 2003 
2 G14S/ c.1128-6_1188dup67 asymptomatic n.a. Lee 2013 
3 W179R/W179R asymptomatic 
26 
7 
20 
Haberle 2002 
Haberle 2002 
Dimmock 2008 
4 W179R/W179R mild 7.5 Haberle 2002 
5 W179R/R279X asymptomatic * n.a. Dimmock 2008 
6 W179R/R307C asymptomatic n.a. Haberle 2003 
7 R265H/R265H mild n.a. Gao 2003 
8 R265H/R279X mild n.a. Gao 2003 
9 R265H/952delG mild n.a. Gao 2003 
10 R304W/R304W neonatal n.a. 
Kakinoki 1997 
Lee 2013 
11 R304W/ c.1128-6_1188dup67 neonatal n.a. Lee 2013 
12 R304W/IVS-6-2A>G neonatal n.a. Kakinoki 1997 
13 R304W/ΔExon7 neonatal 
2.1 
7 
Kobayashi 1994 
14 R304W/R363L neonatal <5 Kobayashi 1994 
15 G324S/G324S neonatal n.a. Gao 2003 
16 G324S/G324S asymptomatic ** n.a. Haberle 2003 
17 G324S/ IVS-6-2A>G neonatal n.a. Lee 2013 
18 G324S/V263M asymptomatic 0.5 Dimmock 2008 
19 G324S/R363W 
Neonatal 
 
n.a. Kobayashi 1990 
20 R363L/R304W neonatal <5 Kobayashi 1994 
21 G390R/G390R neonatal <1 
Gao 2003 
Haberle 2003 
Vilaseca 2001 
22 G390R/G117D mild n.a. 
Gao 2003 
Vilaseca 2001 
23 G390R/Y190D asymptomatic n.a. Haberle 2003 
24 G390R/W179R mild n.a. Gao 2003 
25 G390R/R272H asymptomatic n.a. Dimmock 2008 
26 G390R/Y291S mild 0 Dimmock 2008 
27 G390R/T389I mild <10 Gao 2003 
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Table 20. List of missense mutations analyzed, associated clinical phenotypes and 
activity of the ASS1 enzyme measured by an indirect assay with 14C-citrulline 
according to Kleijer et al. 1984. 
* Patient 5 was treated with a restricted protein diet. 
** Patient 16 was subjected to a restricted protein diet, supplementation of 
arginine, isoleucine and treated with phenylbutyrate. 
 
The mutations studied involve residues with different conservation degree in the  
species (Figure 29). 
The 3D structure of ASS1 protein was analyzed in silico in order to understand 
the effects of the mutations studied: they can interfere with the active site, with 
the interaction between monomers or destabilize the protein peripheral loops. 
In our study we considered the crystallized structure of the bacterial 
argininosuccinate synthase enzyme of Thermus thermophilus, a orthologian of the 
human ASS1 with a homology degree of 53% (Karlberg et al., 2008). It was 
crystallized as a tetramer with its substrates , including ATP (Goto et al., 2002). 
 
 
Figure 29. Alignments of patients’s sequences with the mutations studied, with 
the protein’s sequences in the different species. 
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Table 21 summarizes the possible effects of missense mutations analyzed, 
hypothesized according to molecular modeling and to what reported by Gao et al., 
2003. 
 
Mutation Mutation locus/possible effect of the mutation 
G14S Active site/ATP binding 
W179R β-sheet 9, close to active site/citrulline binding 
R265H close to active site / Folding of the synthesis domain 
R304W Dimer-dimer interactions 
G324S Elica α10 breaker/Dimer-dimer interactions 
R363L β-sheet 16 close to the dimer’s interface/Dimer-dimer interactions 
G390R C-terminal α-helix/oligomerization  
Table 21. Mutations studied and their localization in the protein. 
 
 
4.5.1.  Functional complementation of ASS1 in yeast 
The studies of functional complementation in model organisms are useful in order 
to analyze complex metabolic pathways and to validate the pathogenicity of 
missense mutations present in patients affected by genetic diseases. 
Functional complementation occurs when a gene product (in our study the human 
gene ASS1) is able to compensate for the lack of a gene (in our study the yeast 
gene ARG1). 
To be able to use this approach it is necessary that the heterologous expression 
allows to restore the activity of the gene deleto, and that the corresponding 
phenotype is easily measurable (in our case growth/non-growth of the yeast strain 
for ARG1 in selective medium without arginine). This creates a simple model that 
can be used to study the pathogenicity of the different mutants, evaluating their 
residual activity and determining possible genotype-phenotype correlations. 
The protein encoded by the ASS1 gene is highly conserved in the different species 
and has a 51% identity with the corresponding orthologian encoded by the yeast 
ARG1 gene (Figure 18). 
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With the functional complementation test we have shown that ASS1 is able to 
partially complement the haplous yeast strain bearing a deletion of the ARG1 gene 
and consequently auxotrophic for arginine. 
The coding region of the ASS1 gene and the S. cerevisiae ARG1 homologue gene 
were subcloned in the galactose-inducible pYES.2 expression vector containing 
the selection marker URA3. 
The deaf yeast strain for the ARG1 gene was transformed with the two constructs 
(pYES.2_ASS1 and pYES.2_ARG1) and with the empty vector (pYES.2 ø) as a 
negative control. 
After inoculating the yeasts transformed into minimal medium containing 2% 
galactose and the amino acids for which the strain is auxotrophic (SM GAL2% 
HMLR), they were incubated overnight at 30 ° C to promote the over-expression 
of the recombinant genes . 
The growth test (Drop test) was performed in minimum medium containing 2% 
galactose, or 2% raffinose added with 0.1% galactose, to which were added the 
amino acids for which the strain is auxotrophic but not the arginine (SM GAL2% 
HML and SM RAF2% -GAL0.1% HML). As a control the same test was 
performed also in the presence of arginine (SM GAL2% HMLR). 
The growth occurred in these conditions is indicative of the successful functional 
complementation, which in the specific case of the ASS1 gene appears to be 
partial: the restoration of the growth defect of the ASS1-delete strain is observed 
after about 10 days and is evident until the fourth dilution (10
-3
) under over-
expression (Figure30A) and up  to the second dilution (10
-1
) at baseline 
expression conditions (Figure 30B). As a further check, the test was performed 
also in the medium to which arginine was added (Figure 30BC). 
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Figure 30. Functional complementation test in arginine-free medium containing 
2% galactose (SM GAL2% HLM) [A] and in arginine-free medium containing 
2% raffinose and 0.1% galactose (SM RAF2% GAL 0. 1% HLM) [B], to evaluate 
the complementary capacity of the transformed strains. The vector containing the 
ARG1 yeast gene was used as a positive control and the empty pYES.2 vector 
was a negative control. [C] The same experiment was repeated in the presence of 
arginine. The plates were incubated at 28 ° C for about 10 days. 
 
 
 
 
 
A 
C 
B 
119 
 
4.5.2.  ASS1 has no toxic effect in yeast 
It was then verified whether the partial complementation of ASS1 achieve any 
toxic effects of human gene expression in yeast. 
For that reason, the BY4741 MatA wild type yeast strain was transformed with the 
pYES.2_ASS1 and pYES.2_ARG1 vectors and the growth test (Drop test) was 
performed under the different conditions used in the previous functional 
complementation test (Figure 31). 
The wild type strain transformed with the empty pYES.2 vector was used as a 
control. 
The growth of the ASS1 transformed strain with is comparable to the control and 
to ARG1, this excludes that the partial complementation of the human gene in 
yeast is due to toxicity phenomena. 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. Functional complementation test in arginine-free medium containing 
2% galactose (SM GAL2% HLM) [A] and in arginine-free medium containing 
2% raffinose and 0.1% galactose (SM RAF2% GAL0. 1% HLM) [B] to evaluate 
the complementary capacity of the BY4741 MatA wild-type strains transformed 
with the indicated constructs. The plate was incubated for 6 days at 28 ° C. 
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4.5.3.  Effect of ASS1 gene mutations on yeast complementation 
Functional complementation experiments were then performed using the ΔARG1 
yeast strain to study the growth phenotype of some missense mutations identified 
in patients with CTLN1. This test is based on the fact that the growth of the ARG1 
delete yeast strain in minimal arginine-free medium can occur only in the 
presence of residual enzymatic activity of ASS1. 
The seven mutations reported in this study were introduced into the pCR8 TOPO 
TA vector by site-specific mutagenesis and were subsequently transferred into the 
pYES.2 expression vector by LR recombination reaction (Gateway system). 
These constructs were used to transform the ΔARG1 yeast strain and the ability of 
the transformants to grow in the absence of arginine under different expression 
conditions was analyzed (2% galactose or 2% raffinose added with 0.1% 
galactose). As controls, the delete strain was also transformed with  the yeast 
ARG1 gene, with the human wild type ASS1 gene and with the empty vector. 
In these conditions, different growth profiles were observed (Figure 32) that allow 
to distinguish the alleles analyzed in two classes: 
- Class I mutations: absence of growth in minimal medium, both in over-
expression conditions (Figure 32A) and in basal conditions (Figure 32B). 
The G14S, W179R, R363L and G390R mutations belong to this class. 
- Class II mutations: residual growth in minimal medium under over-
expression conditions (Figure 32A) and marked reduction/abolition of 
growth at basal conditions (Figure 32B). The R265H, R304W and G324S 
mutations belong to this class. 
The test was performed also in the presence of arginine (Figure 32E). 
To evaluate the yeast phenotype transformed with the G324S mutant expressing 
construct, which showed a weak growth at the first dilution, the plates were 
incubated at 28 °C for 5 additional days. As shown in Figure 32, this allele allows 
residual growth of the yeast (evident until the second dilution) only after induction 
with galactose (Figure 32C), but not under basal conditions (Figure 32D). 
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Figure 32. Functional complementation test in arginine-free medium containing 
2% galactose (SM GAL2% HLM) [A] [C] and in arginine-free medium 
containing 2% raffinate and 0.5% galactose (SM RAF2 % GAL0.1% HLM) [B] 
[D] to evaluate the complementary capacity of ASS1 mutated transformed strains. 
ASS1 wild-type was used as a positive control, and pYES.2 empty as negative 
control. The plate was incubated at 28 °C for 9 [A] and [B] or for 15 days [C] and 
[D]. The same experiment was repeated in the presence of arginine [E], incubating 
the plates at 28 °C for about 10 days. 
D C 
E 
B A 
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4.5.4.  Effect of ASS1 mutations on protein stability 
After the complementation analysis of the various mutations in different 
conditions of expression (using media containing galactose and raffinose), we 
examined the levels of ASS1 protein produced by the different mutant alleles, by 
western blot analysis (Figure 33). 
The densitometric analysis performed shows that the protein encoded by the 
R304W allele is stable, those expressed by the alleles R265H and G324S are 
partially stable, while the mutations G14S, W179R, R363L and G390R 
considerably destabilize the protein, as demonstrated by the absence or the 
markedly reduced levels of protein shown by the immunoblot. 
 
Figure 33. Western blot analysis to measure the stability of wild-type and mutated 
ASS1 protein. The proteins were extracted from the respective yeasts and 
subsequently detected using the corresponding antibody. The densitometric 
analysis was performed using the ImageJ program, normalizing the data by 
referring to pYES.2_ASS1 wild-type. 
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5. CONCLUSIONS 
 
In the last 3 years in the Genetic Unit of Hospital of Padua we have worked to 
introduce the Next Generation Sequencing technologies into clinical routine. 
The comparative analysis of the NGS technologies TruSeq Custom Amplicon Low 
Input Library Prep Kit (Illumina) and HaloPlex HS Target Enrichment System 
(Agilent Technologies) showed how the second one is more efficient in diagnostic, 
considering the followed parameters: coverage, results variability, pseudogenes 
and false positive discrimination, number of amplicons generated for the analysis. 
For these reason, from 2017 we use only the HaloPlex HS Target Enrichment 
System (Agilent Technologies). 
The main diseases analyzed in our laboratory are: metabolic diseases (from 
neonatal and non-neonatal screening), mitochondrial diseases from nuclear genes 
and mitochondrial DNA, RASopathies, neurofibromatosis type 1 and type 2, 
schwannomatosis, Marfan syndrome and related syndromes, long QT syndrome 
and related syndromes, craniofacial anomalies, peripheral neuropathies, spinal 
muscular atrophy, hypertrophic cardiomyopathies, deafness (syndromic and non), 
porphyrias. The new generation sequencing technologies represent a valid strategy 
for the analysis of these diseases, allowing to significantly reduce the time and 
costs involved in the analysis, in fact the NGS technology turns out to be the most 
rapid approach for the analysis of rare genetic diseases because it allows to study 
several variants in genes (that could be also of large dimensions) related to the 
pathology at the same time. In contrast at the conventional Sanger sequencing 
approach in these cases would be rather complex due to the large number of genes 
potentially causing the observed phenotype. 
This technology has proved useful also for the molecular analysis of patients 
positive at the neonatal metabolic screening. In this study, we analyzed 85 patients 
positive at the neonatal metabolic screening for Mucopolysaccharidosis type I 
(MPS I) or for Biotinidase Deficiency or Phenylketonuria (PKU), by Next 
Generation Sequencing: molecular analysis made it possible to distinguish true 
positive patients from false positives to neonatal metabolic screening, allowing to 
avoid unnecessary therapies and significantly reduce the cost of the investigation.  
124 
 
The increasing number of variants identified in the post-genomic era, in particular 
following the introduction of Next Generation Sequencing technology, has been 
accompanied by significant difficulties in the interpretation of the same, making 
fundamental the development of methods for their functional characterization. 
Notable difficulties of interpretation are encountered especially for the intronic 
variants, especially if they are outside from the canonical splicing sites. Molecular 
analyzes based on mRNA have also highlighted how some exonic mutations 
(missense, synonymous and nonsense) are incorrectly classified as they actually 
interfere with the splicing mechanism (Messiaen and Wimmer, 2008). 
In the absence of functional tests, to evaluate the pathogenicity of a variant we 
take in consideration some parameters including the absence of other pathogenic 
variants in the entire gene (including deletions or duplications), absence of the 
variant in healthy controls, the degree of conservation of the amino acid involved 
and the type of change, the genotype-phenotype segregation (absence of variant in 
unaffected parents and presence in all affected family members) (Messiaen and 
Wimmer, 2008). The use of predictive software can also help in the evaluation of 
pathogenicity (PolyPhen, SIFT, etc.) (Adzhubei et al., 2013). 
In this study we used an experimental approach for the validation of a new variant 
identified in the COQ4 gene able to altering the splicing, this method consists in 
the analysis of transient expression in human cells of hybrid minigens: these are 
constructs formed by recombinant DNA artificially designed, in which the coding 
sequence of the gene of interest is associated with regulatory elements present in 
the vector, which allow the expression of the insert and the production of the 
desired protein. 
Our hybrid-minigene validation system has shown that this mutation behaves like 
a hypomorphic allele, in fact the analysis with hybrid minigen has shown that the 
splicing leads to the production of both the wild-type transcript and an abnormal 
transcript with loss of about 100 bp of COQ4 exon 4. 
In this study it was also studied a missense mutations of the ASS1 gene, identified 
in patients affected by CTLN1 with heterogeneous clinical phenotypes, by 
functional complementation in yeast model system. 
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After verifying that the heterologous expression of the human gene ASS1 was able 
to correct the growth defect in arginine-free medium of a ΔARG1 yeast strain, it 
was analyzed the ability of the various ASS1 mutant alleles to restored the ΔARG1 
yeast growth. 
The phenotypic analysis allowed: 
1) to confirm the pathogenicity of all the mutations under study; 
2) to classify the mutants into two classes: 
- class I mutations that completely abolish yeast growth; 
- class II mutations that allow a residual growth. 
The effect of missense mutations on the stability of the protein was evaluated by 
western blot analysis. 
The results of the study are summarized in Table 22. 
 
Allele 
Clinical 
picture of 
patients 
Protein 
localization 
Yeast growth 
ability 
Protein 
stability 
G14S asymptomatic Active site - - / + 
W179R 
asymptomatic, 
mild 
Active site - - 
R265H mild Active site ++ ++ 
R304W neonatal 
Dimer-dimer 
interactions 
++ +++ 
G324S 
asymptomatic, 
neonatal 
Dimer-dimer 
interactions 
+ ++ 
R363L neonatal 
Dimer-dimer 
interactions 
- - / + 
G390R 
asymptomatic, 
mild, neonatal 
Oligomerization - - / + 
Table 22. Summary of the characteristics of missense mutations analyzed in this 
study.  
The results demonstrate that: the mutations G14S, W179R, R363L and G390R 
abolish the function of the human gene in yeast and have a marked effect on the 
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stability of the protein, abolishing (W179R) or significantly reducing (G14S, 
R363L and G390R) the levels of protein; the mutations R265H, R304W and 
G324S, on the other hand, allow a residual growth of the ΔARG1 yeast strain, 
proving to maintain a greater stability of the protein. 
These results confirm the absence of a clear correlation between the residual 
enzymatic activity (measured indirectly by analysis of functional 
complementation in yeast) and the clinical picture presented by the patients (age 
of onset, severity of the manifestations). In fact, the presence of high levels of 
residual activity of ASS1 can not be considered a reliable marker of a 
mild/asymptomatic clinical course. 
In particular, patients with mild late-onset or asymptomatic forms with a 
biochemical phenotype, may present class I mutations (for example G14S or 
W179R in homozygosity or in compound heterozygosis) while, conversely, the 
presence of a class II mutation (for example R304W or G324S) is not sufficient to 
guarantee a mild phenotype. 
In this last case it is possible to hypothesize that the nucleotide substitution 
involves an aberrant effect on the ASS1 gene splicing, with the consequent 
formation of an null alelle. It will be interesting to test this hypothesis for the two 
class II mutations listed above (c.970G> A p.G324S and c.910C> T p.R304W) 
using an in vivo expression system based on hybrid minigens (Trevisson et al., 
2007). 
In conclusion, the yeast model developed was useful for testing the pathogenicity 
of ASS1 gene missense mutations, but not for establishing correlations between 
the genotype and the phenotype of patients. 
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